[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2017053864A1 - Cysteine protease inhibitors - Google Patents

Cysteine protease inhibitors Download PDF

Info

Publication number
WO2017053864A1
WO2017053864A1 PCT/US2016/053539 US2016053539W WO2017053864A1 WO 2017053864 A1 WO2017053864 A1 WO 2017053864A1 US 2016053539 W US2016053539 W US 2016053539W WO 2017053864 A1 WO2017053864 A1 WO 2017053864A1
Authority
WO
WIPO (PCT)
Prior art keywords
ome
tfa
compound
fmk
vad
Prior art date
Application number
PCT/US2016/053539
Other languages
French (fr)
Inventor
David Phelps
Gary Johnson
Mary Margaret BARTIK
Eric S. BENSEN
David J. HALVERSON
Matthew S. Bogyo
Original Assignee
Intracellular Technologies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intracellular Technologies, Llc filed Critical Intracellular Technologies, Llc
Publication of WO2017053864A1 publication Critical patent/WO2017053864A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Definitions

  • Apoptosis is a complex mechanism of programmed cell death that is controlled by multiple biochemical events leading to morphological cell changes and eventual cell death.
  • the apoptosis process begins when apoptotic signals cause regulatory proteins to initiate an apoptosis pathway.
  • the primary pathways targeted include mitochondrial functionality, transduced signals via adaptor proteins to the apoptotic mechanism, and drug induced increases in calcium within the cell.
  • Apoptosis culminates in coordinated cell death that requires energy and, unlike cell death occurring by necrosis, does not induce an inflammatory response.
  • Apoptosis is a critical event in numerous processes within the body. For example, embryonic development relies on apoptosis, and tissues that turn over rapidly require tight regulation to avoid serious pathological consequences.
  • Certain medical conditions, such as cancer are characterized by insufficient apoptosis (insufficient cell death) and uncontrolled cell proliferation brought on in part by the failure to regulate apoptosis.
  • apoptosis can be induced by various means.
  • chemical induction of apoptosis can be achieved by administering drugs such as chemotherapeutic agents that initiate apoptosis.
  • excess apoptosis can damage organs.
  • Apoptosis can also be indicative of tissue damage, such as damaged heart tissue following ischemia or reperfusion insults.
  • Inflammation is an organism's reaction to harmful stimuli, such as pathogens, damaged cells, or irritants, and an attempt by the organism (e.g. a human body) to initiate a healing process and remove the cause of the inflammation.
  • An inflammatory reaction typically involves an organism's local vascular system, immune system, and cells within the injured tissue.
  • Chronic inflammation is characterized by a shift in cell types at the site of inflammation and simultaneous destruction and healing of tissue.
  • Cellular pathways leading to both apoptosis and inflammation involve the activation of members of a family of proteases known as caspases. At least 14 members of the caspase family have been identified in vertebrates, and at least 8 are known to be involved in apoptotic cell death (see Saunders, et ah, Anal. Biochem., 284, 114-24 (2000)).
  • Caspases are a group of highly specific cysteine proteases that cleave aspartic acid peptide bonds within proteins. Caspases collaborate in the proteolytic cascade by activating themselves and each other.
  • Apoptosis-related caspases can be divided into two categories: "initiator” caspases (e.g., caspase-2, caspase-8, caspase-9 and caspase- 10), and downstream “effector” caspases (e.g., caspase-3, caspase-6, caspase-7 and caspase-14).
  • Initiator caspases mediate their oligomerization and autoactivation in response to specific upstream signals, and can activate effector caspases by cleaving their inactive pro-forms.
  • Activated effector caspases continue the apoptotic process by cleaving protein substrates within a cell.
  • Inhibitors of caspases can thus regulate the initiation and/or effector enzymes within the apoptotic caspase chain reaction by inhibiting these processes.
  • caspases e.g., caspase-1 , caspase-4, caspase-5, caspase-1 1 and caspase-13
  • caspase-1 inflammation-related caspase
  • caspase-1 inflammation-related caspase
  • ICE-1 converting enzyme ICE-1
  • the detection of active caspases involved in inflammatory pathways indicates an acute or chronic inflammatory response - e.g., inflammation associated with inflammatory diseases such as rheumatoid arthritis or atherosclerosis.
  • peptidic pan- caspase inhibitors such as Z-VAD-FMK have routinely been used in vitro in scientific research and drug development screening to block caspase activity.
  • a more potent caspase inhibitor may prove valuable for in vitro testing, in that it may allow for the use of less product and potentially shorten test duration.
  • caspase inhibitors have been shown in various animal models to inhibit post myocardial infarction apoptosis, to reduce lesion volume and neurological deficit resulting from stroke or ischemia, to reduce post-traumatic apoptosis and neurological deficit in traumatic brain injury (TBI), and to be effective in treating fulminant liver destruction, liver disease and sepsis (see e.g. Yaoita et al. (1998) Circulation, 97: 276-281 ; Endres et al. (1998) J. Cerebral Blood Flow and Metabolism, 18: 238-247; Cheng et al. (1998) J. Clin. Invest. 101 : 1992-1999; Yakovlev et al. (1997) J.
  • pan caspase inhibitor emricasan (a potent inhibitor of both apoptotic and inflammatory caspases) has recently been investigated as a therapeutic in various models of liver disease. Recent research efforts also include the use of caspase inhibitors in combination with various therapeutics for the treatment of cancer (ref: Brumatti et al., The Caspase-8 Inhibitor Emricasan Combines With the SMAC Mimetic
  • caspase inhibitors may someday be used in vivo as potential therapeutics for certain conditions involving apoptosis and/or inflammation, including (but not limited to) neurodegenerative diseases such as Alzheimer's and Multiple Sclerosis, liver disease, spinal atrophy, stroke, traumatic brain injury, myocardial infarction, fibrotic diseases (kidney fibrosis, idiopathic pulmonary fibrosis, diabetic nephropathy, liver fibrosis, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), systemic sclerosis, corneal fibrosis), and inflammatory conditions related to metabolic disease.
  • neurodegenerative diseases such as Alzheimer's and Multiple Sclerosis, liver disease, spinal atrophy, stroke, traumatic brain injury, myocardial infarction, fibrotic diseases (kidney fibrosis, idiopathic pulmonary fibrosis, diabetic nephropathy, liver fibrosis, non-alcoholic steatohepatit
  • caspase inhibitors in vivo has met with considerable challenges involving undesirable pharmacological effects and cytotoxicity, due in part to the dose of inhibitor required to achieve a sufficient anti-apoptotic and/or anti-inflammatory effect.
  • Available information suggests the need for safe, stable, caspase-selective, cell-permeant, irreversible caspase inhibitors with increased potency (i.e. enhanced caspase binding affinity and kinetics), suitable for both in vitro and in vivo
  • Inflammatory pathways also involve the expression of a family of proteases called cathepsins.
  • the cysetine cathepsins in particular (cathepsins B, C, F, H, K, L, O, S, W, X/Z) are often highly upregulated or overexpressed during conditions where inflammation is present, such as cancer (especially with tumor invasion, angiogenesis, metastasis, or tumor associated macrophages (TAMS) in the tumor microenvironment), auto-immune diseases (e.g. lupus, psoriasis, Crohn's disease, Sjogren's syndrome, celiac disease), neurodegenerative diseases (e.g.
  • Alzheimers traumatic brain injury, arthritis, hepatitis (including alcohol-related and NASH), pancreatitis, liver fibrosis and steatosis (including HCV-associated), pulmonary fibrosis, renal fibrosis and cardiac fibrosis (ref: Golde et al., Science 255: 728-730, 1992; Munger et al., Biochem. J. 31 1 : 299-305, 1995; Iwata et al., Arthritis and Rheumatism 40: 499-509, 1997; Yan et al, Biol. Chem.
  • cysteine cathepsins (like caspases) play a critical role in a number of diseases, they are increasingly becoming attractive targets for numerous therapeutic agents.
  • cathepsin expresion involves the use of peptidic or synthetic cathepsin inhibitors which bind to (and as a result, inhibit the activity of) cysteine cathepsins.
  • cysteine cathepsin inhibitors are used in vitro in scientific research and drug development screening.
  • cathepsin inhibitors such as Z-FA-FMK (for cathepsin B) are widely available and have been used extensively for in vitro applications.
  • more potent cathepsin inhibitors may prove valuable for in vitro testing, in that they may allow for the use of less product and potentially shorten test duration.
  • cysteine cathepsins in vivo for therapeutic purposes is a continuing effort, with several commercial projects currently focusing on inhibition of cathepsin B, L, S or K for various clinical applications such as neuropathic pain and Alzheimers, liver fibrosis (associated with HCV, non-alcoholic steatohepatititis or "NASH", alcoholic steatohepatitis, non-alcoholic fatty liver disease), cirrhosis, and various conditions associated with metabolic disease.
  • HCV non-alcoholic steatohepatititis or "NASH”
  • alcoholic steatohepatitis non-alcoholic fatty liver disease
  • cirrhosis various conditions associated with metabolic disease.
  • cysteine cathepsins are also upregulated in cells within the tumor environment, such as tumor associated macrophages (TAMs).
  • TAMs tumor associated macrophages
  • Cathepsin inhibitors which can also target upregulation of cathepsins in the tumor microenvironment might someday represent a viable approach to cancer prevention or treatment, and cathepsin inhibitor compounds designed to target both the tumor and tumor microenvironment have already been proposed (ref: Mikhaylov, et al. Ferri- Liposomes as a Novel MRI- Visible Drug Delivery System for Targeting Tumours and their Microenvironment, Nat.
  • Cathepsin inhibitors have also been used as anti-viral agents. Examples of cathepsin inhibitors used to block virus replication were illustrated in Van der Linden, et al., Cysteine Cathepsins as Anti-Ebola Agents. ACS Infect. Dis., 2016, 2 (3), pp 173-179 and in US2009/0203629A1 (Hepatitis C related). Recent studies suggest that blocking cathepsin activity may not only address the inflammation and tissue injury associated with some viruses such as HCV, but also the overall viral burden itself.
  • cathepsin inhibitors As with caspase inhibitors, there is a need for safe, stable, selective, cell-permeant, cathepsin inhibitors with increased potency (i.e. enhanced cathepsin binding affinity and kinetics), suitable for both in vitro and in vivo applications.
  • the present invention provides compositions and methods for caspase and cysteine cathepsin inhibition.
  • a new class of highly potent, cell membrane permeant, anti- apoptotic and/or anti-inflammatory peptide based caspase and cathepsin inhibitors is provided.
  • the compounds of this invention are capable of forming irreversible covalent bonds to the active site of a caspase or cysteine cathepsin and inhibiting the activity of that enzyme.
  • HTS high throughput screening
  • HTS high throughput screening
  • Another potential application is the inhibition of caspase or cysteine cathepsin activity in a cell-free system by adding any one of the compounds described in the invention to the purified caspase(s) or cathepsin(s) that it targets.
  • Another potential application is in the treatment of a variety of mammalian disease states or conditions associated with an increase in cellular apoptosis and/or inflammation, including (but not limited to) myocardial infarction, stroke, traumatic brain injury, fulminant liver destruction, endotoxic shock, sepsis, septic shock, chronic hepatitis (including virus related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH”), pancreatitis, viral infection, fibrosis, implant or transplant rejection, auto-immune diseases, arthritis, neurological conditions (e.g. Alzheimer's Disease), cancer, and ototoxicity.
  • myocardial infarction stroke, traumatic brain injury, fulminant liver destruction, endotoxic shock, sepsis, septic shock, chronic hepatitis (including virus related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH
  • the invention provides a compound of formula (I):
  • Ui is absent or is a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms
  • U 2 is absent or is a fluorinated group comprising 1 -10 carbon atoms and one or more fluorine atoms; wherein at least one of Ui and U 2 is present;
  • X is a molecule that will recognize a cysteine protease
  • J is a reactive group that binds to a cysteine protease.
  • One aspect of the invention concerns a method for preventing and/or treating a caspase- mediated or cathepsin-associated disease or condition in a subject in need thereof, comprising administering to said subject an effective amount of a compound represented by any of the above molecules.
  • Another related aspect of the invention concerns the use of a compound represented by any of the above molecules for the manufacture of a medication for the prevention and/or treatment of caspase-mediated or cathepsin-associated diseases or conditions in a subject in need thereof.
  • One aspect of the invention concerns a method of treating excessive apoptosis or inflammation affected by caspase activity in a cell or a tissue, the method comprising: contacting the cell or tissue with an effective amount of one or more compounds represented by any of the above formulas.
  • a final aspect of the invention concerns the use of a compound represented by any of the above molecules to inhibit caspase or cathepsin activity in a cell-free system.
  • FIG. 1 TFA-VAD(OMe)-FMK vs Z-VAD(OMe)-FMK vs Q-VD-OPH, Percent Inhibition of Caspase 3 at Varying Inhibitor Concentration.
  • Competition Assay using active Caspase-3 and Ac- V AD- AFC Enzo Lifesciences. Fluorescence kinetic reads performed with a Microplate Reader (M2e, Molecular Devices).
  • FIG. 3 Structure of TFA-VAD(OMe)-FMK (aka Trifluoroacetyl-L-valyl-L-alanyl-L- aspartic acid methyl ester fluoromethyl ketone).
  • TFA-VAD(OMe)-FMK is more potent at inhibiting staurosporine-induced caspase activity compared to Z-VAD(OMe)-FMK and Q-VD(OMe)-FMK.
  • Inhibitors (10 uM) were added to Jurkat cells (human T lymphocyte cell line) for 15 minutes. 1 uM Staurosporine (protein kinase inhibitor) was then added for 3.5 hours to induce apoptosis. After 3.5 hours, CAS-MAP active caspase labeling reagent (FAM-VAD(OMe)-FMK) was added for 20 minutes. Cells were then analyzed by flow cytometry. An increase in FAM-VAD-FMK fluorescence intensity correlates with caspase activity.
  • TFA-VAD(OMe)-FMK is more potent than Z-VAD(OMe)-FMK at inhibiting apoptosis.
  • Jurkat cells were incubated with the indicated concentrations of TFA-VAD(OMe)- FMK or Z-VAD(OMe)-FMK for 15 minutes prior to stimulation with 1 ⁇ Staurosporine for 4 hours, 5 ⁇ Camptothecin (topoisomerase I inhibitor) for 4 hours or 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours.
  • Cells were labeled with Annexin V - Alexa Fluor 488 and a cell impermeable DNA dye (SYTOX AADvanced) and analyzed by flow cytometry.
  • TFA-VAD(OMe)-FMK inhibits staurosporine-induced apoptosis after 24 hours in cell culture.
  • Jurkat cells were incubated with 10 ⁇ TFA-VAD(OMe)-FMK or 10 ⁇ TFA-VAD(OMe)-FMK for 24 hours in RPMI 1640 media with 10% FBS. After 24 hours, cells were stimulated for 4 hours with 1 ⁇ staurosporine to induce apoptosis followed by labeling with Annexin V - Alexa Fluor 488 and a cell impermeable DNA dye (SYTOX AADvanced). Stained cells were analyzed by flow cytometry. % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations.
  • TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit caspase-3/7 activity in Hep G2 cells (human hepatocyte carcinoma cell line).
  • Hep G2 cells were incubated with the indicated concetrations of caspase inhibitor for 15 minutes prior to a 24 hour treatment with 2 ⁇ g/ml anti-TRAIL R2 agonist antibody to induce caspase activity.
  • a caspase-3/7 specific fluorescent substrate MP39 was added to each sample in a duel function cell lysis/caspase activity buffer.
  • TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit staurosporine-induced apoptosis in Jurkat cells.
  • Jurkat cells were incubated with 5 ⁇ of the indicated caspase inhibitor for 15 minutes prior to stimulation with 1 ⁇ staurosporine for 4 hours.
  • EVD-TPH and TFA-6E8D-TPH inhibit anti-TRAIL R2 antibody-induced apoptosis in Jurkat cells.
  • Jurkat cells were incubated with the indicated concentrations of caspase inhibitor for 15 minutes prior to stimulation with 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours.
  • Cells were labeled with Annexin V - Alexa Fluor 488 and a cell impermeable DNA dye (SYTOX AADvanced) and analyzed by flow cytometry.
  • FIG. 10 RAW 264.7 cells were incubated with TFA-FK-TPH, TFA-FR-TPH or E64d at the indicated concentrations for 1 hour prior to a 2 hour incubation with 1 ⁇ BMV109. Cells were then collected, lysed in hypotonic lysis buffer and protein concentrations were determined. 50 ⁇ g of cell lysate was separated by SDS-PAGE on 15% Mini-PROTEAN TGX precast gels (Bio Rad). Gels were scanned using a Typhoon FLA 9500 (Cy5).
  • the present disclosure relates to cysteine protease inhibitors that covalently bind to cysteine proteases (e.g. active caspases or cathepsins), and methods of using such inhibitors to block caspase-mediated apoptosis, caspase-mediated inflammation, and cathepsin expression associated with any of the cathepsin related conditions mentioned herein.
  • the present disclosure further relates to kits comprising the present cysteine protease inhibitors and instructions for their use.
  • F is a small and dense atom, only about 10% bigger in diameter than hydrogen and fluorine-containing molecules are hydrophobic.
  • biological sample refers to any type of material of biological origin, including but not limited to a blood sample, tissue sample, cell suspension, cellular extract, or tissue homogenate.
  • cysteine protease includes enzymes that degrade proteins using a nucleophilic cysteine thiol.
  • the cysteine protease is a caspase or cysteine cathepsin.
  • the cysteine protease is a caspase.
  • the cysteine protease is a cysteine cathepsin.
  • in vitro refers to processes or procedures performed on a biological sample outside a living organism.
  • in vitro administration includes administering (i.e., delivering, applying, etc.) a cysteine protease inhibitor to a biological sample that is outside a living organism.
  • m vivo refers to processes or procedures performed inside a living, multicellular organism.
  • in vivo administration includes administering a cysteine protease inhibitor to a living subject (e.g., a mammal, such as a human).
  • incidence refers to the occurrence rate, frequency of an event, or the quantifiable degree to which an event occurs.
  • incubating when used with respect to incubating a sample with a cysteine protease inhibitor, refers to exposure conditions (e.g., time, temperature, pH, etc.) sufficient for the formation of caspase-inhibitor or cathepsin-inhibitor complexes.
  • N-terminal group refers to a moiety attached to the N- terminal position of the recognition sequence of the cysteine protease inhibitor.
  • the N-terminal group in the caspase inhibitors (and certain cathepsin inhibitors) of this invention is a
  • C-terminal group refers to a moiety attached to the C-terminal position of the recognition sequence of the cysteine protease inhibitor.
  • reactive group that binds to a cysteine protease includes groups that are capable of interacting with or reacting with the catalytic site of a cysteine protease.
  • a reactive group is capable of interacting with or reacting with the catalytic site of a caspase or cysteine cathepsin. In one embodiment, a reactive group is capable of forming a covalent bond with a cysteine protease. In one embodiment, a reactive group is capable of forming a covalent bond with a caspase or cysteine cathepsin. In one embodiment, a reactive group is a leaving group that can be displaced to form a covalent bond. In one embodiment, for example, the reactive group can be FMK, PMK, OPH, or TPH.
  • the reactive group can be a halogen atom, a substituted or unsubstituted phenol group, a substituted or unsubstituted benzoylate group, a substituted or unsubstituted BMK group, a substituted or unsubstituted FMK group, and a substituted or unsubstituted PMK group.
  • the reactive group can be a halogen atom (e.g. F or CI) or a (C 1 -C4) alkyl group that is substituted with one or more halogen atoms.
  • the reactive group can be a portion of a cysteine protease inhibitor that covalently binds to the active catalytic site of a cysteine protease.
  • recognition sequence refers to a portion of the cysteine protease inhibitors comprising a sequence of 1 to 8 natural or unnatural amino acids or synthetic analogs thereof, which is selective for one or more cysteine proteases.
  • amino acid refers to a (chemically) substituted natural amino acid, an unsubstituted unnatural amino acid, or a substituted unnatural amino acid.
  • unnatural amino acid refers to an amino acid (or conformation thereof) not normally found in nature (i.e. not found in the genetic code of any organisms, not encoded into proteins). Synthetic analogs are a type of unnatural amino acid.
  • substituted means the group is substituted with one or more (e.g., 1 , 2, 3, 4 or 5) substituents independently selected from halo, cyano, nitro, carboxy, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C] -C 4 ) haloalkoxy, (Ci-C 4 ) alkanoyl, (CrC 4 ) alkoxycarbonyl, (CrC 4 ) alkanoyloxy, amino, (CrC 4 ) alkylamino, and ((C ! -C 4 )alkyl) 2 amino.
  • substituents independently selected from halo, cyano, nitro, carboxy, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C] -C 4 )
  • AOMK acyloxymethyl ketone
  • BMK benzoyloxymethyl ketone
  • DE L-aspartyl-L-glutamic acid
  • FK phenylalyl lysine
  • LAD L-leucyl-L-alanyl-L-aspartic acid
  • TD L-threonyl-L-aspartic acid
  • VAD L-valyl-L-alanyl-L-aspartic acid
  • VD L-valyl-L-aspartic acid
  • the N-terminal group may serve to protect the recognition sequence during synthesis of a cysteine protease inhibitor.
  • an N-terminal protecting group may be present during synthesis of an intermediate precursor of a cysteine protease inhibitor, but may be removed and replaced with a different N-terminal moiety - i.e., the N-terminal group of a cysteine protease inhibitor intermediate may be different from the N-terminal group of a final cysteine protease inhibitor.
  • the N-terminal group on final caspase inhibitors and some final cysteine cathepsin inhibitors described in this invention is a trifluoroacetyl (TFA) group.
  • the trifluoroacetyl (TFA) group is located on the C-terminal end of the Recognition Sequence. It is believed that a TFA group on the N-Terminal or C-Terminal position of a peptide based cysteine protease inhibitor enhances binding to the enzyme and/or enhances cell membrane permeability of the cysteine protease inhibitor.
  • Each recognition sequence comprises one or more natural or unnatural, synthetically modified amino acids and is able to bind to one or more caspases or cysteine cathepsins.
  • amino acids of the recognition sequence may be L, D, or D/L racemates.
  • a recognition sequence may allow the cysteine protease inhibitor to target structurally similar caspases or cysteine cathepsins with the same or different affinities and kinetics.
  • the recognition sequence VAD valine-alanine-aspartic acid
  • VAD valine-alanine-aspartic acid
  • caspase inhibitors containing the VAD recognition sequence will covalently bind to all or most active caspases.
  • the caspase inhibitor is designed to react with multiple caspases to allow inhibition of all or most caspases.
  • the FK recognition sequence is designed to react with multiple cysteine cathepsins (B/L/S/X/Z). Accordingly, the FK containing cysteine cathepsin inhibitors described herein are considered "poly" cysteine cathepsin inhibitors.
  • the caspase inhibitor is designed to react selectively with caspase- 1, thus allowing for detection of inflammation in particular.
  • caspase inhibitors containing the recognition sequence WEHD (SEQ ID NO:l) or YVAD (SEQ ID NO:2) will bind covalently to caspase-1 over other apoptosis-associated caspases.
  • the caspase inhibitor is designed to react with two caspases that have similar substrate selectivity.
  • caspase inhibitors containing the recognition sequence DEVD SEQ ID NO:3 will recognize and allow detection of both caspase-3 and caspase-7.
  • the caspase inhibitor recognition sequence is selected from inhibitor recognition sequences listed in Table 1.
  • Table 1 identifies well known recognition sequences of caspase inhibitors disclosed herein and their corresponding ability to selectively bind to all or most active caspases (i.e., poly-caspase), inflammation-related active caspases (e.g., caspase-1), or apoptosis-related active caspases (e.g., caspase-3/7 or caspase-8).
  • the molecule that will recognize a cysteine protease is selected from:
  • Examples of synthetic or "unnatural” amino acids include (but are not limited to):
  • the cysteine cathepsin inhibitor recognition sequence is FK, FR, GGR (including synthetic analogs thereof). Reactive Group - Binding Mechanism to Active Caspase (Illustrative Example)
  • a multi-step binding mechanism results in the formation of a covalent bond between the reactive group and the -SH moiety of the cysteine residue in the active catalytic site of the caspase.
  • the caspase inhibitor binds irreversibly and covalently to the caspase.
  • the caspase inhibitors comprise a reactive group that enables the inhibitor to covalently bind to an active caspase.
  • the reactive group includes a moiety that leaves as the reactive group reacts with the active caspase.
  • the reactive group can be tailored to recognize and bind to specific types of caspases, such as caspases associated with apoptosis, caspases associated with inflammation, or caspases associated with both.
  • a representative example of the multi-step binding mechanism is illustrated below for caspase inhibitors that comprise a ketone that reacts with the cysteine residue in the catalytic site of an active caspase.
  • This same general mechanism applies to cysteine cathepsin inhibitors described in this invention.
  • the epoxysuccinyl group irreversibly binds to an active thiol group on target cysteine cathepsins to form a thioether linkage.
  • the caspase inhibitors (and select cysteine cathepsin inhibitors) of the present disclosure have the following general structure: (U)-X-J-(U), where U must be present on at least one end of the molecule and may be attached directly or indirectly (i.e. via linker) to the C-terminal and/or N-terminal end of the molecule, and where U is a fluorinated group or perfluoroalkyl group comprising 1-10 carbon atoms and one or more fluorine atoms (e.g. a trifluoroacetyl (TFA) group); X is any molecule that will recognize a cysteine protease (e.g.
  • J is any reactive group that binds to a caspase or cysteine cathepsm (e.g. a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy- methyl ketone a.k.a. "TPH” or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH”), an acyloxy- methyl ketone a.k.a. "AOMK” or an epoxide).
  • a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy- methyl ketone
  • the caspase inhibitors of the present disclosure are further described by the following formula:U-X-NH-CH(R)-CO-CH 2 -J,where U is any fluorinated group or perfluoroalkly group (e.g. a trifluoroacetyl (TFA) group), X is any molecule that will recognize an active caspase (e.g.
  • R is CH2- C02-CH3 for live cells and in vivo applications or CH2-C02-H for cell-free systems
  • J is any molecule that will react with active caspases; for example, a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy-methyl ketone a.k.a. "TPH” or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH”), an acyloxy-methyl ketone a.k.a. "AOMK” or an epoxide).
  • FMK fluoro-methyl ketone
  • PMK phenoxy-methyl ketone
  • PH 2,6 difluoro phenoxy-methyl ketone
  • U comprises the N-terminal group
  • X-NH-CH(R)-CO-CH 2 comprises the recognition sequence
  • J comprises the reactive group
  • X is selected from one or more naturally occurring amino acids, one or more synthetic amino acids and combinations thereof.
  • X may be one or more amino acids selected from alanine, aspartic acid, glutamic acid, histidine, glycine, arginine, lysine, methionine, proline, isoleucine, phenylalanine, leucine, threonine, tryptophan, valine, tyrosine, glutamine, serine, pyrrolysine, selenocysteine, norvaline, norleucine and synthetic analogs thereof (where applicable).
  • J is capable of binding at least one caspase selected from caspase- 1 , caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase- 10, caspase- 1 1, caspase- 12, caspase- 13 and caspase- 14.
  • J may be selected from BMK, FMK, PMK, OPH, TPH and AOMK.
  • J is capable of binding at least one caspase selected from caspase- 1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase- 10, caspase- 1 1, caspase- 12, caspase- 13 and caspase- 14.
  • J may be selected from FMK, PMK, OPH, TPH and AOMK.
  • J is capable of binding to at least one cysteine cathepsin selected from Cathepsins B, C, F, H, K, L, O, S, W, X/Z. J may be selected from FMK, PMK, OPH, TPH and AOMK.
  • J is selected from a halogen, a phenol group, a benzoylate group, a BMK group, an FMK group, and a PMK group, in which the groups mentioned herein may be substituted or unsubstituted.
  • J is selected from BMK, FMK, and PMK.
  • the J halogen is F, CI, or Br.
  • the J phenol is a compound of Formula A:
  • X 1? X 2 , X 3 , X 4 , and X 5 is each individually selected from H, F, CI, alkyl, aryl, aralkyl, amino, nitro, and carboxy.
  • at least one of Xj, X 2 , X 3 , X , and X5 is H.
  • alkyl is C 1-10 alkyl, for example, Ci -6 alkyl.
  • the J benzoylate is a compound of Formula B:
  • X 1? X 2 , X 3 , X 4 , and X 5 is each individually selected from H, F, CI, alkyl, aryl, aralkyl, amino, nitro, or carboxy.
  • at least one of X], X 2 , X 3 , X 4 , and X 5 is H.
  • alkyl is C 1-10 alkyl, for example, Ci -6 alkyl.
  • the cysteine protease inhibitor has a molecular weight of about 300- 1500 Daltons.
  • the cysteine protease inhibitors are typically cell permeant (i.e., exhibit good cell membrane permeability) and can typically selectively target cysteine proteases (i.e. caspases and cysteine cathepsins) of interest inside the cells of a living organism or a biological sample.
  • cysteine proteases i.e. caspases and cysteine cathepsins
  • the cysteine protease inhibitors do not undergo facile metabolism, and possess a long half-life (e.g., more than 6 hours) throughout the life of the permeated cell.
  • each cysteine protease inhibitor forms a metabolite having the formula U-X-NH-CH(R)-CO-CH 2 -S-Cys-Enzyme, wherein U, X, and R are as defined above.
  • caspase inhibitors of the present disclosure includes, but is not limited to TFA-VAD(OMe)-FMK:
  • cysteine cathepsin inhibitors of the present disclosure include, but are not limited to:
  • cysteine protease inhibitors examples include, but are not limited to: eye, breast, heart, brain and central nervous system (CNS), kidneys, lungs, liver, skin, pancreas, skeletal system, connective tissue (e.g., joints), stomach, upper gastrointestinal tract, lower gastrointestinal tract, circulatory system (e.g., blood), lymphatic system, sexual organs (male and female), prostate, embryologic tissue, muscular system, and gallbladder.
  • the cysteine protease inhibitor is delivered in vitro to a biological sample (e.g., a blood sample, tissue sample, cell suspension, cellular extract, or tissue homogenate) by direct application of the inhibitor to the sample.
  • a biological sample e.g., a blood sample, tissue sample, cell suspension, cellular extract, or tissue homogenate
  • the cysteine protease inhibitors exhibit good cell permeability, there is no need to use additional reagents to facilitate the entry of the inhibitors into cells.
  • the cysteine protease inhibitor is reconstituted in DMSO, further diluted in phosphate buffered saline (PBS) or cell culture media and applied directly to cells in a cell culture dish.
  • PBS phosphate buffered saline
  • the cysteine protease inhibitor is allowed to incubate with the cells under the conditions sufficient for the formation of caspase-inhibitor complexes.
  • the cysteine protease inhibitor is administered in vivo to a subject (e.g., animal or human) intravenously, intraperitoneally, intramuscularly, subcutaneously, topically, and/or by direct application to a target organ.
  • the cysteine protease inhibitor is diluted with a suitable excipient (in some cases a pharmaceutically acceptable excipient) and administered in an effective amount, which is an amount that is sufficient to provide meaningful results with respect to the intended purpose - e.g., therapeutic, drug development, etc.
  • Suitable excipients include, but are not limited to, adhesives, binders, bulking agents, carriers, colors, diluents, disintegrating agents, fillers, glidants, granulating agents, lubricating agents, polymers, preservatives, wetting agents, and combinations thereof.
  • One or more excipients may be selected from sucrose, lactose, cellulose, methyl cellulose, gelatin, polyvinylpyrrolidone, polyethylene glycol and water. Kits
  • kits of the present disclosure are used for blocking apoptotic activity and/or conditions associated with inflammatory activity in a biological sample.
  • the kit may comprise one or more cysteine protease inhibitors.
  • the kit may further include packaging materials with instructions for using the components of the kit, such as how to use the cysteine protease inhibitors provided in the kit, storage conditions, etc.
  • Components of the kit may be provided in separate containers (e.g., vials) or combined.
  • the invention relates to a kit containing instructions for use and at least one cysteine protease inhibitor compound of the following formula: (U)-X-J-(U), where at least one U must be present and where U may be attached either directly or indirectly (i.e. via linker) to the C-terminal or N-terminal end of the molecule, and where U is a fluorinated group or perfluoroalkyl group comprising 1-10 carbon atoms and one or more fluorine atoms (e.g. a trifluoroacetyl (TFA) group);
  • X is any molecule that will recognize a cysteine protease (e.g.
  • J is any reactive group that binds to a caspase or cysteine cathepsin (e.g. a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy- methyl ketone a.k.a. "TPH” or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH”), an acyloxy- methyl ketone a.k.a. "AOMK” or an epoxide).
  • a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy- methyl ketone
  • the invention relates to a kit containing instructions for use and at least one caspase inhibitor compound of the following formula: U-X-NH-CH(R)-CO-CH 2 -J, where U is any fluorinated group or perfluoroalkly group (e.g. a trifluoroacetyl (TFA) group), X is any molecule that will recognize an active caspase (e.g. a peptide having 1-8 amino acids or synthetic analogs thereof), R is CH2-C02-CH3 for live cells and in vivo applications or CH2- C02-H for cell-free systems, and J is any molecule that will react with active caspases, e.g.
  • U any fluorinated group or perfluoroalkly group (e.g. a trifluoroacetyl (TFA) group)
  • X is any molecule that will recognize an active caspase (e.g. a peptide having 1-8 amino acids or synthetic analogs thereof)
  • R is CH2-
  • a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy-methyl ketone ("TPH”) or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH”), an acyloxy-methyl ketone a.k.a. "AOMK” or an epoxide).
  • FMK fluoro-methyl ketone
  • PMK phenoxy-methyl ketone
  • TPH 2,3,5,6 tetrafluoro phenoxy-methyl ketone
  • OHPH 2,6 difluoro phenoxy-methyl ketone
  • AOMK acyloxy-methyl ketone
  • epoxide an epoxide
  • the "X" for the caspase or cysteine cathepsin inhibitor comprises at least one amino acid selected from alanine, aspartic acid, glutamic acid, histidine, glycine, arginine, lysine, methionine, proline, isoleucine, phenylalanine, leucine, threonine, tryptophan, valine, tyrosine, glutamine, serine, pyrrolysine, selenocysteine, norvaline, norleucine and synthetic analogs thereof (where applicable).
  • the compound is selected from the group consisting of:
  • the compound is selected from the group consisting of:
  • the compound is selected from the group consisting of:
  • the compound is selected from the group consisting of:
  • the compound contains an epoxide based "J" reactive group and is selected from the group consisting of:
  • the compound contains at least one cathepsin inhibitor and is selected from the group consisting of:
  • the present invention relates to a composition
  • a composition comprising a caspase inhibitor or cysteine cathepsin inhibitor and an excipient (which may be selected from sucrose, lactose, cellulose, gelatin, polyvinylpyrrolidone, trehalose, cyclodextrin, hyaluronic acid, polyethylene glycol, DMSO and water.
  • an excipient which may be selected from sucrose, lactose, cellulose, gelatin, polyvinylpyrrolidone, trehalose, cyclodextrin, hyaluronic acid, polyethylene glycol, DMSO and water.
  • the present invention relates to a method of inhibiting apoptosis and/or inflammation in a living organism by administering in vivo a caspase inhibitor or cathepsin inhibitor to the living organism.
  • the present invention relates to a method of inhibiting apoptosis and/or inflammation in a cell population by administering in vitro a caspase inhibitor or cathepsin inhibitor to a biological sample and incubating the sample with the inhibitor under conditions sufficient to form caspase-inhibitor complexes.
  • the biological sample may be selected from a blood sample, tissue sample, cell suspension, cellular extract, or tissue homogenate.
  • the compound is a compound of formula (la): UrX-J (la).
  • the compound is a compound of formula (lb):
  • X is a molecule that will recognize a caspase or cysteine cathepsin.
  • X is a peptide that contains 1-8 amino acids.
  • X is a peptide that contains 2-5 amino acids.
  • X is a peptide selected from the group consisting of: VD, VAD, EVD, D-3-V-D, L-E-H-D (SEQ ID NO:9), L-E-T-D (SEQ ID NO: 10), D-E-V-D (SEQ ID NO:3), D-E-P-D (SEQ ID NO:7), D-29-V-D, D-34-V-D, 26-34-V-D, 26-3-V-D, 26-E-V-D, 31- E-T-D, 31-E-23-D, 29-E-T-D, 6-E-8-D, D-E-1 1-D, D-30-11-D, D-30-V-D, P-L-A-D (SEQ ID NO:8), I-L-A-D (SEQ ID NO:l 1), I-L-38-D, I-F-P-D (SEQ ID NO:12), D-3-V-D, D-34-V-D,
  • J is selected from the group consisting of AMOK, BMK, FMK, OPH, PMK, and TPH.
  • J is selected from the group consisting of AMOK, OPH, PMK, and TPH.
  • J is TPH.
  • the compound is selected from the group consisting of: TFA- EVD-TPH; TFA-6E8D-TPH; TFA-VAD(OMe)-TPH; TF A- VD(OMe)-TPH ; TFA-FK-TPH; and TFA-F -TPH.
  • the compound is a compound of formula (Id): (U)-X-J-(U) (Id)
  • U is present on at least one end of the molecule and consists of a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms;
  • X is any molecule that will recognize a cysteine protease
  • J is any reactive group that binds to a caspase or cysteine cathepsin.
  • U is a trifluoroacetyl (TFA) group that may be connected directly or indirectly (i.e. via linker) to either the C-terminal end or to the N-terminal end J group.
  • TFA trifluoroacetyl
  • the compound is a compound of formula (Ie): (U)-X-NH-CH(R)-CO-CH 2 -J(U) (Ie)
  • U is a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms
  • X is a peptide-based caspase recognition sequence comprising 1-8 amino acids;
  • R is -CH 2 C0 2 CH 3 , -CH 2 C0 2 H;
  • J is any reactive group that binds to a caspase.
  • U is a trifluoroacetyl (TFA) group that may be connected directly or indirectly (i.e. via linker) to either the C-terminal end or to the N-terminal end J group.
  • TFA trifluoroacetyl
  • X comprises at least one amino acid selected from alanine, aspartic acid, glutamic acid, histidine, glycine, arginine, lysine, methionine, proline, isoleucine, phenylalanine, leucine, threonine, tryptophan, valine, tyrosine, glutamine, serine, pyrrolysine, selenocysteine, norvaline, norleucine and synthetic analogs thereof (where applicable).
  • X comprises VAD(OMe), VD(OMe), VAD, VD,
  • X is VAD(OMe), VD(OMe), VAD, VD, E(OMe)VD(OMe), EVD, 6E8D, 6E(OMe)8D(OMe), FK, FR, GGR, WE(OMe)HD(OMe), IE(OMe)TD(OMe), D(OMe)E(OMe)VD(OMe), LE(OMe)HD(OMe), LE(OMe)TD(OMe), YVAD(OMe),
  • VD(OMe)VAD(OMe) or any of the following: Asp-3,4 Difluorophenylalanine- Val-Asp, Asp- Pentafluorophenylalanine- Val-Asp, (2-Oxoacetamido)(Propanamido)-4-Oxo-Pentanoic Acid, (Oxiran-2-yl) Carbonyl-L-Leucyl-3-(p-Hydroxyphenyl) Ethylamide.
  • J is any molecule that will react with active cysteine proteases, e.g.a halomethyl ketone (such as CMK, FMK), a substituted or unsubstituted phenoxymethyl ketone (PMK), an acyloxymethyl ketone (AOMK), or an epoxide.
  • active cysteine proteases e.g. a halomethyl ketone (such as CMK, FMK), a substituted or unsubstituted phenoxymethyl ketone (PMK), an acyloxymethyl ketone (AOMK), or an epoxide.
  • the compound is selected from:
  • TFA-GGR-TPH TFA-FK-TPH TFA-FR-TPH TFA-GGR-AOMK TFA-FK-AOMK TFA-FR-AOMK and the following compounds:
  • the compound is a compound of formula (If):
  • X is a peptide that will recognize a caspase or cysteine cathepsin.
  • the compound is a compound of formula (If):
  • X is a peptide that contains 1-8 amino acids.
  • the compound is a compound of formula (If):
  • X is a peptide that contains 2-5 amino acids.
  • the compound is a compound of formula (If):
  • X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V- D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E-8D(OMe), V-A-D(OMe).
  • X is a peptide selected from the group consisting of:
  • E(OMe)-V-D E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E- 8D(OMe), V-A-D(OMe).
  • X is a peptide selected from the group consisting of:
  • X is a peptide selected from the group consisting of:
  • J is acyloxymethyl, benzoyloxymethyl, fluoromethyl, 2,6- difluorophenoxymethyl, phenoxymethyl, or 2,3,5,6-tetrafluorophenoxymethyl, which form AMOK, BMK, FMK, OPH, PMK, or THP, respectively, when attached to the carboxy carbonyl group of X in a compound of the invention.
  • a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable excipient, and optionally a therapeutic agent.
  • the excipient comprises sucrose, lactose, cellulose, gelatin, polyvinylpyrrolidone, trehalose, cyclodextrin, hyaluronic acid, polyethylene glycol or water.
  • the therapeutic agent is a cancer-targeted chemotherapeutic agent.
  • a method for inhibiting a cysteine protease in vitro or in vivo comprises contacting the cysteine protease with a compound of the invention.
  • a method for inhibiting a cysteine protease in vitro or in vivo comprises contacting the caspase with a compound of the invention.
  • the compound inhibits the cysteine protease by forming an irreversible covalent bond to the active site of a cysteine protease.
  • a method for treating a disease or condition associated with an increase in cellular apoptosis and/or inflammation in a subject comprises administering to the subject a compound of the invention.
  • the disease or condition is myocardial infarction, stroke, traumatic brain injury, spinal atrophy, auto-immune diseases (e.g.
  • liver disease such as chronic hepatitis (including virus-related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH"), pancreatitis, arthritis, viral infection, metabolic disease, cancer, implant or transplant rejection,
  • chronic hepatitis including virus-related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH”
  • pancreatitis arthritis
  • viral infection metabolic disease
  • cancer implant or transplant rejection
  • neurodegenerative diseases e.g. multiple sclerosis
  • pulmonary fibrosis pulmonary fibrosis
  • cardiac fibrosis pulmonary fibrosis
  • renal fibrosis pulmonary fibrosis
  • liver fibrosis cirrhosis or ototoxicity.
  • a method for inhibiting apoptosis and/or inflammation in another embodiment, a method for inhibiting apoptosis and/or inflammation
  • a subject e.g. animal or human
  • administering comprises administering to the subject a compound of the invention.
  • a method for inhibiting apoptosis and/or inflammation in a cell population comprises administering in vitro a compound of the invention to a biological sample to provide a resulting sample, and incubating the resulting sample under conditions sufficient to form caspase-inhibitor or cysteine cathepsin-inhibitor complexes.
  • the biological sample comprises blood sample, tissue, a cell suspension, a cellular extract, or a tissue homogenate.
  • a method for preventing and/or treating a caspase-mediated or cysteine cathepsin-associated disease or condition in an subject comprises administering to the subject a compound of the invention.
  • a kit comprising:
  • a kit comprising:
  • a method of inhibiting caspase or cysteine cathepsin activity in a cell-free system comprises adding a compound of the invention to the purified caspases.
  • the compounds of the invention e.g. the compounds of formula
  • N-AM-G-F 6 V-AD-BMK N-AM-G-F 6 V-AD-FMK
  • BODIPY-FL-D(OMe)E(OMe)VD(OMe)-FMK BODIPY-FL-IE(OMe)TD(OMe)-FMK
  • BODIPY-FL-LE(OMe)HD(O e)-FMK BODIPY-FL-LE(OMe)TD(OMe)-FMK
  • BODIPY-FL-VAD(OMe)-FMK BODIPY-FL-D(OMe)E(OMe)VD(OMe)-FMK
  • BODIPY-FL-D(OMe)E(OMe)VD(OMe)-PMK BODIPY-FL-IE(OMe)TD(OMe)-PMK, BODIPY-FL-LE(OMe)HD(OMe)-PMK, BODIPY-FL-LE(OMe)TD(OMe)-PMK, BODIPY-FL-VAD(OMe)-PMK,
  • BODIPY-FL-VD(OMe)VAD(OMe)-PMK BODIPY-FL-F 6 V-AD(OMe)-PMK
  • BODIPY-FL-D(OMe)E(OMe)VD(OMe)-BMK BODIPY-FL-IE(OMe)TD(OMe)-BMK
  • TFMCBZ-GWE(OMe)HD(OMe)-FMK TFMCBZ-GWE(OMe)HD(OMe)-BMK
  • TFMCBZ-GWE(OMe)HD(OMe)-PMK TFMCBZ-GWE(OMe)HD(OMe)-OPH
  • TFMCBZ-GYVAD(OMe)-FMK TFMCBZ-GYVAD(OMe)-BMK
  • TFMCBZ-GYVAD(OMe)-PM TFMCBZ-GYVAD(OMe)-OPH
  • the caspase inhibitors can be synthesized using liquid phase peptide synthesis (Bodanszky, PRINCIPLES OF PEPTIDE SYNTHESIS (1993) or solid phase peptide synthesis (Merrifield, J Amer Chem Soc 85(14):2149-54 (1963); Amblard et al., Mol. Biotechnol., 33(3):239-54 (2006)).
  • a suitable liquid phase peptide synthetic pathway is shown below, and generally involves building oligo peptides from the N-terminus of an amino acid by providing a first amino acid (1); protecting or blocking the N terminus of the amino acid using a protecting or blocking group (e.g., BOC or FMOC); coupling the first amino acid with a C-terminal ester of a second amino acid (2) by reacting the amino acids in the presence of a coupling agent (e.g., dicyclohexyl carbodiimide (DCC), diisopropyl carbodiimide (DIC), usually in the presence of N-hydroxysuccinimide or 1 -hydroxybenzotriazole) to form a dipeptide (3); and deprotecting the dipeptide without removing any other protecting groups to yield the free dipeptide acid (4).
  • a coupling agent e.g., dicyclohexyl carbodiimide (DCC), diisopropyl carbodiimide (DIC), usually in the presence of
  • Dipeptide (4) can be coupled to the suitably derivatized L- aspartic acid ⁇ -methyl ester to yield a desired caspase inhibitor or it can be coupled with a suitably protected amino acid to yield a fully protected tripeptide (5). If desired, by sequential deprotection of the C-terminus of 5 and analogous coupling to another suitably protected amino acid, a fully protected tetrapeptide may be constructed.
  • Synthesized caspase inhibitors disclosed herein may be in the form of a waxy material or lyophilized powder.
  • the caspase inhibitor may be prepared by finishing the peptide chain with an aspartic acid portion and adding a fluoromethyl ketone (FMK), phenoxymethyl ketone (PMK), an OPH (2,6-difluorophenoxy ketone or 2,6-difluorophenoxymethyl ketone) group, or an acyloxymethyl ketone (AOMK) to the end of the peptide chain as a leaving group that is part of the reactive group and is positioned at the C-terminus of the recognition sequence of the caspase inhibitor.
  • FMOC-L-aspartic acid ⁇ -methyl ester may be made. From these molecules, FMK/PMK/OPH/AOMK can be attached to the a-carboxylic acid via a methylene group, introduced using diazomethane chemistry.
  • Solubility 1 mg/mL in 10% Acetonitrile in H 2 0
  • TFA-VAD(OMe)-FMK is more potent than Z-VAD(OMe)-FMK and Q- VD(OMe)-OPH at inhibiting purified caspase-3.
  • Inhibitors and substrate were mixed in assay buffer (50 niM HEPES pH 7.2, 50 mM NaCl, 0.1% CHAPS, 10 mM EDTA, 5% glycerol, 10 mM DTT) in 96-well plates.
  • TFA-VAD(OMe)-FMK is more potent at inhibiting staurosporine-induced caspase activity compared to Z-VAD(OMe)-FMK and Q-VD(OMe)-FMK.
  • Inhibitors (10 ⁇ ) were added to 1 x 10 6 Jurkat cells (human T lymphocyte cell line) for 15 minutes in a total volume of 1 ml cell culture medium (RPMI + 10% FBS) at 37°C. 1 ⁇ Staurosporine (protein kinase inhibitor) was added and cells were incubated for 3.5 hours at 37°C to induce apoptosis. After 3.5 hours, CAS-MAP active caspase labeling reagent (FAM- VAD(OMe)-FMK, 0.75 ⁇ ) was added and cells were incubated for 20 minutes at 37°C to label active caspases.
  • FAM- VAD(OMe)-FMK 0.75 ⁇
  • TFA-VAD(OMe)-FM is a more potent than Z-VAD(OMe)-FMK at inhibiting apoptosis.
  • Jurkat cells (1 x 10 6 cells, 1 ml total volume in RPMI + 10% FBS) were incubated at 37°C with the indicated concentrations of TFA-VAD(OMe)-FMK or Z-VAD(OMe)-FMK for 15 minutes prior to apoptosis induction with 1 ⁇ Staurosponne (protein kinase inhibitor) for 4 hours at 37°C, 5 ⁇ Camptothecin (topoisomerase I inhibitor) for 4 hours at 37°C or 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours at 37°C.
  • Staurosponne protein kinase inhibitor
  • Camptothecin topoisomerase I inhibitor
  • annexin V binding buffer 140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4
  • annexin V - Alexa Fluor 488 was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes.
  • 1 ml of annexin V binding buffer was added to each sample followed by 1 ⁇ SYTOX AADvanced (Thermo Scientific).
  • TFA-VAD(OMe)-FMK inhibits staurosporine-induced apoptosis after 24 hours in cell culture.
  • Jurkat cells (1 x 10 6 cells, 1 ml total volume in RPMI + 10% FBS) were incubated with 10 ⁇ TFA-VAD(OMe)-FMK or 10 ⁇ Z-VAD(OMe)-FMK for 24 hours at 37°C. After 24 hours, apoptosis was induced with 1 ⁇ staurosporine for 4 hours at 37°C.
  • Cells were washed with annexin V binding buffer (140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4) and resuspended in 100 ⁇ annexin V binding buffer.
  • annexin V binding buffer 140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4
  • Annexin V - Alexa Fluor 488 was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes. 1 ml of annexin V binding buffer was added to each sample followed by 1 ⁇ SYTOX AADvanced (Thermo Scientific). Cells were incubated in the dark, at room temperature
  • NxT acoustic focusing cytometer (488 nm excitation laser, 530 nm 30 nm band pass emission filter for annexin V- Alexa Fluor 488 and 488 nm excitation laser, 695 nm/40 nm band pass emission filter for SYTOX AADvanced).
  • % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. ( Figure 6)
  • TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit caspase-3/7 activity in Hep G2 cells.
  • Hep G2 cells human hepatocyte carcinoma cell line
  • Inhibitors were added to the indicated concentrations and cells were incubated for 15 minutes at 37°C.
  • Caspase activity was induced by treating cells with 2 ⁇ ⁇ anti-TRAIL R2 agonist antibody for 24 hours at 37°C in a total volume of 60 ⁇ in DMEM + 10% FBS.
  • TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH and TFA-VD(OMe)-TPH inhibit staurosporine-induced apoptosis in Jurkat cells.
  • Jurkat cells (1 x 10 6 cells, 1 ml total volume in RPMI + 10% FBS) were incubated with 5 ⁇ of the indicated caspase inhibitor for 15 minutes prior to stimulation with 1 ⁇
  • annexin V binding buffer 140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4
  • annexin V - Alexa Fluor 488 was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes.
  • 1 ml of annexin V binding buffer was added to each sample followed by 1 ⁇ SYTOX AADvanced (Thermo Scientific).
  • TFA-EVD-TPH and TFA-6E8D-TPH inhibited apoptosis to a lesser extent than TFA-VAD-FMK, TFA-VAD-TPH and TFA-VD-TPH in staurosporine-induced Jurkat cells. ( Figure 8)
  • TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit anti-TRAIL R2 antibody-induced apoptosis in Jurkat cells.
  • Jurkat Cells (1 x 10 6 cells, 1 ml total volume in RPMI + 10% FBS) were incubated with the indicated concentrations of caspase inhibitor for 15 minutes prior to stimulation with 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours at 37°C.
  • Cells were washed with annexin V binding buffer (140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4) and resuspended in 100 ⁇ annexin V binding buffer. 5 ⁇ Annexin V - Alexa Fluor 488 (Thermo Scientific) was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes.
  • annexin V binding buffer 1 ml was added to each sample followed by 1 ⁇ SYTOX AADvanced (Thermo Scientific). Cells were incubated in the dark, at room temperature for 5 minutes prior to flow cytometry analysis using a Life Technologies Attune NxT acoustic focusing cytometer (488 nm excitation laser, 530 nm/30 nm band pass emission filter for annexin V- Alexa Fluor 488 and 488 nm excitation laser, 695 nm/40 nm band pass emission filter for SYTOX
  • RAW 264.7 cells (mouse macrophage cell line) were plated in 6 well plates at 8 x 10 cells/well in DMEM + 10% FBS and allowed to grow overnight at 37°C. The next day, cells were treated with the indicated concentrations of TFA-FK-TPH, TFA-FR-TPH or E64d (a general cysteine cathepsin and calpain inhibitor) for 1 hour at 37°C followed by the addition of 1 ⁇ BMV109 (a Cy5 labeled activity based probe that binds cathepsin B, L, S and X) for 2 hours at 37°C to label active cathepsins.
  • TFA-FK-TPH TFA-FR-TPH
  • E64d a general cysteine cathepsin and calpain inhibitor
  • Representative compounds of the invention can also be prepared as illustrated below.
  • Intermediate compound 110 can be used to prepare compounds having D-TPH at the carboxy terminus. Similar intermediate compounds can be prepared to provide compounds having the functionality X-J at the carboxy terminus, wherein X is an amino acid or an appropriately protected amino acid and J has any of the values defined herein, by selection of the starting amino acid 101.
  • Solid-phase peptide synthesis can be used to prepare peptide sequences that can be incorporated in to compounds of the invention. Coupling of the carboxy terminus of a peptide sequences 111 with an intermediated of formula 110 followed by optional deprotection and optional functionalization of the N-terminus can provide compounds of the invention as illustrated below. 1. Solid-phase peptide synthesis (SPPS)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides compounds and compositions that inhibit one or more cysteine proteases (e.g. caspases or cysteine cathepsins), as well as kits comprising such compounds and compositions. The invention also provides therapeutic methods and screening methods that utilize such compounds and compositions.

Description

CYSTEINE PROTEASE INHIBITORS
PRIORITY
This application claims priority to United States Provisional Application Number 62/222,586, filed 23 September 2015 and to United States Provisional Application Number 62/344,251 , filed 01 June 2016. The entire content of these United States Provisional
Applications is hereby incorporated herein by reference.
BACKGROUND
Apoptosis is a complex mechanism of programmed cell death that is controlled by multiple biochemical events leading to morphological cell changes and eventual cell death. The apoptosis process begins when apoptotic signals cause regulatory proteins to initiate an apoptosis pathway. The primary pathways targeted include mitochondrial functionality, transduced signals via adaptor proteins to the apoptotic mechanism, and drug induced increases in calcium within the cell. Apoptosis culminates in coordinated cell death that requires energy and, unlike cell death occurring by necrosis, does not induce an inflammatory response.
Apoptosis is a critical event in numerous processes within the body. For example, embryonic development relies on apoptosis, and tissues that turn over rapidly require tight regulation to avoid serious pathological consequences. Certain medical conditions, such as cancer, are characterized by insufficient apoptosis (insufficient cell death) and uncontrolled cell proliferation brought on in part by the failure to regulate apoptosis. In treating such conditions, apoptosis can be induced by various means. For example, chemical induction of apoptosis can be achieved by administering drugs such as chemotherapeutic agents that initiate apoptosis. In some medical conditions, including neuropathies such as Alzheimer's disease, excess apoptosis can damage organs. Apoptosis can also be indicative of tissue damage, such as damaged heart tissue following ischemia or reperfusion insults.
Inflammation is an organism's reaction to harmful stimuli, such as pathogens, damaged cells, or irritants, and an attempt by the organism (e.g. a human body) to initiate a healing process and remove the cause of the inflammation. An inflammatory reaction typically involves an organism's local vascular system, immune system, and cells within the injured tissue.
Chronic inflammation is characterized by a shift in cell types at the site of inflammation and simultaneous destruction and healing of tissue. Cellular pathways leading to both apoptosis and inflammation involve the activation of members of a family of proteases known as caspases. At least 14 members of the caspase family have been identified in vertebrates, and at least 8 are known to be involved in apoptotic cell death (see Saunders, et ah, Anal. Biochem., 284, 114-24 (2000)). Caspases are a group of highly specific cysteine proteases that cleave aspartic acid peptide bonds within proteins. Caspases collaborate in the proteolytic cascade by activating themselves and each other. Apoptosis-related caspases can be divided into two categories: "initiator" caspases (e.g., caspase-2, caspase-8, caspase-9 and caspase- 10), and downstream "effector" caspases (e.g., caspase-3, caspase-6, caspase-7 and caspase-14). Initiator caspases mediate their oligomerization and autoactivation in response to specific upstream signals, and can activate effector caspases by cleaving their inactive pro-forms. Activated effector caspases continue the apoptotic process by cleaving protein substrates within a cell. Inhibitors of caspases can thus regulate the initiation and/or effector enzymes within the apoptotic caspase chain reaction by inhibiting these processes.
Other caspases (e.g., caspase-1 , caspase-4, caspase-5, caspase-1 1 and caspase-13) are involved in inflammatory pathways. One such inflammation-related caspase (i.e., caspase-1) was identified as the IL-1 converting enzyme (ICE-1) required for activation of the IL-1 beta and IL-18 cytokines in inflammatory responses. The detection of active caspases involved in inflammatory pathways indicates an acute or chronic inflammatory response - e.g., inflammation associated with inflammatory diseases such as rheumatoid arthritis or atherosclerosis.
During apoptosis and/or inflammation, high levels of active caspases are expressed. One way to block apoptosis and/or inflammation involves the use of peptidic or synthetic caspase inhibitors, which bind to active caspases within cells. Historically, broad spectrum, peptidic pan- caspase inhibitors such as Z-VAD-FMK have routinely been used in vitro in scientific research and drug development screening to block caspase activity. A more potent caspase inhibitor may prove valuable for in vitro testing, in that it may allow for the use of less product and potentially shorten test duration.
In in vivo applications, caspase inhibitors have been shown in various animal models to inhibit post myocardial infarction apoptosis, to reduce lesion volume and neurological deficit resulting from stroke or ischemia, to reduce post-traumatic apoptosis and neurological deficit in traumatic brain injury (TBI), and to be effective in treating fulminant liver destruction, liver disease and sepsis (see e.g. Yaoita et al. (1998) Circulation, 97: 276-281 ; Endres et al. (1998) J. Cerebral Blood Flow and Metabolism, 18: 238-247; Cheng et al. (1998) J. Clin. Invest. 101 : 1992-1999; Yakovlev et al. (1997) J. Neurosci. 17: 7415-7424; Rodriquez et al. (1996) J. Exp. Med., 184: 2067-2072); Pockros et al. (2007) HEPATOLOGY, Vol. 46, No. 2). More recently, Caserta et al found that Q-VD-OPH, a next generation broad spectrum caspase inhibitor, was significantly more effective in preventing apoptosis in vivo than widely used caspase inhibitors such as Z-VAD-FMK (see Q-VD-OPH, a broad spectrum caspase inhibitor with anti-apoptotic properties. Apoptosis. 2003 Aug 8(4):345-52). Additionally, the pan caspase inhibitor emricasan (a potent inhibitor of both apoptotic and inflammatory caspases) has recently been investigated as a therapeutic in various models of liver disease. Recent research efforts also include the use of caspase inhibitors in combination with various therapeutics for the treatment of cancer (ref: Brumatti et al., The Caspase-8 Inhibitor Emricasan Combines With the SMAC Mimetic
Binnapant to Induce Necroptosis and Treat Acute Myeloid Leukemia, Sci Trans Med 8:339ra69, 2016).
It is hoped that caspase inhibitors may someday be used in vivo as potential therapeutics for certain conditions involving apoptosis and/or inflammation, including (but not limited to) neurodegenerative diseases such as Alzheimer's and Multiple Sclerosis, liver disease, spinal atrophy, stroke, traumatic brain injury, myocardial infarction, fibrotic diseases (kidney fibrosis, idiopathic pulmonary fibrosis, diabetic nephropathy, liver fibrosis, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), systemic sclerosis, corneal fibrosis), and inflammatory conditions related to metabolic disease. However, the use of existing caspase inhibitors in vivo has met with considerable challenges involving undesirable pharmacological effects and cytotoxicity, due in part to the dose of inhibitor required to achieve a sufficient anti-apoptotic and/or anti-inflammatory effect. Available information suggests the need for safe, stable, caspase-selective, cell-permeant, irreversible caspase inhibitors with increased potency (i.e. enhanced caspase binding affinity and kinetics), suitable for both in vitro and in vivo
applications. Inflammatory pathways also involve the expression of a family of proteases called cathepsins. The cysetine cathepsins, in particular (cathepsins B, C, F, H, K, L, O, S, W, X/Z) are often highly upregulated or overexpressed during conditions where inflammation is present, such as cancer (especially with tumor invasion, angiogenesis, metastasis, or tumor associated macrophages (TAMS) in the tumor microenvironment), auto-immune diseases (e.g. lupus, psoriasis, Crohn's disease, Sjogren's syndrome, celiac disease), neurodegenerative diseases (e.g. Alzheimers), traumatic brain injury, arthritis, hepatitis (including alcohol-related and NASH), pancreatitis, liver fibrosis and steatosis (including HCV-associated), pulmonary fibrosis, renal fibrosis and cardiac fibrosis (ref: Golde et al., Science 255: 728-730, 1992; Munger et al., Biochem. J. 31 1 : 299-305, 1995; Iwata et al., Arthritis and Rheumatism 40: 499-509, 1997; Yan et al, Biol. Chem. 379: 113-123, 1998; Joyce et al., Cancer Cell 5: 443-453, 2004; Turk et al., Biochimica et Biophysica Acta. 1824 (2012) 68-88; Hook et al., Frontiers in Neurology 6:article 178, 2015). Because cysteine cathepsins (like caspases) play a critical role in a number of diseases, they are increasingly becoming attractive targets for numerous therapeutic
applications.
One way to block cathepsin expresion involves the use of peptidic or synthetic cathepsin inhibitors which bind to (and as a result, inhibit the activity of) cysteine cathepsins. As with caspase inhibitors, cysteine cathepsin inhibitors are used in vitro in scientific research and drug development screening. For example, cathepsin inhibitors such as Z-FA-FMK (for cathepsin B) are widely available and have been used extensively for in vitro applications. As with caspase inhibitors, more potent cathepsin inhibitors may prove valuable for in vitro testing, in that they may allow for the use of less product and potentially shorten test duration.
Targeting cysteine cathepsins in vivo for therapeutic purposes is a continuing effort, with several commercial projects currently focusing on inhibition of cathepsin B, L, S or K for various clinical applications such as neuropathic pain and Alzheimers, liver fibrosis (associated with HCV, non-alcoholic steatohepatititis or "NASH", alcoholic steatohepatitis, non-alcoholic fatty liver disease), cirrhosis, and various conditions associated with metabolic disease.
In regard to cancer, in addition to the implication of cysteine cathepsin upregulation in tumor metastasis and invasion, mounting evidence suggests that cysteine cathepsins are also upregulated in cells within the tumor environment, such as tumor associated macrophages (TAMs). Cathepsin inhibitors which can also target upregulation of cathepsins in the tumor microenvironment (e.g. within TAMs) might someday represent a viable approach to cancer prevention or treatment, and cathepsin inhibitor compounds designed to target both the tumor and tumor microenvironment have already been proposed (ref: Mikhaylov, et al. Ferri- Liposomes as a Novel MRI- Visible Drug Delivery System for Targeting Tumours and their Microenvironment, Nat. Nanotechnol., 6 (2011), pp. 594-602; Salpeter, et al. A Novel Cysteine cathepsin inhibitor Yields Macrophage Cell Death and Mammary Tumor Regression, Oncogene, (2015), 1 -13).
Cathepsin inhibitors have also been used as anti-viral agents. Examples of cathepsin inhibitors used to block virus replication were illustrated in Van der Linden, et al., Cysteine Cathepsins as Anti-Ebola Agents. ACS Infect. Dis., 2016, 2 (3), pp 173-179 and in US2009/0203629A1 (Hepatitis C related). Recent studies suggest that blocking cathepsin activity may not only address the inflammation and tissue injury associated with some viruses such as HCV, but also the overall viral burden itself.
As with caspase inhibitors, there is a need for safe, stable, selective, cell-permeant, cathepsin inhibitors with increased potency (i.e. enhanced cathepsin binding affinity and kinetics), suitable for both in vitro and in vivo applications.
SUMMARY
The present invention provides compositions and methods for caspase and cysteine cathepsin inhibition. In particular, a new class of highly potent, cell membrane permeant, anti- apoptotic and/or anti-inflammatory peptide based caspase and cathepsin inhibitors is provided. The compounds of this invention are capable of forming irreversible covalent bonds to the active site of a caspase or cysteine cathepsin and inhibiting the activity of that enzyme.
One potential application of the invention is in cell based high throughput screening (HTS) testing where rapid inhibition of the apoptotic or inflammatory pathway is desired.
Another potential application is in cell based high throughput screening (HTS) testing where minimal concentration of inhibitor is desired.
Another potential application is the inhibition of caspase or cysteine cathepsin activity in a cell-free system by adding any one of the compounds described in the invention to the purified caspase(s) or cathepsin(s) that it targets.
Another potential application (for the pharmaceutically acceptable derivatives of these compounds) is in the treatment of a variety of mammalian disease states or conditions associated with an increase in cellular apoptosis and/or inflammation, including (but not limited to) myocardial infarction, stroke, traumatic brain injury, fulminant liver destruction, endotoxic shock, sepsis, septic shock, chronic hepatitis (including virus related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH"), pancreatitis, viral infection, fibrosis, implant or transplant rejection, auto-immune diseases, arthritis, neurological conditions (e.g. Alzheimer's Disease), cancer, and ototoxicity.
In one embodiment the invention provides a compound of formula (I):
Figure imgf000006_0001
wherein: Ui is absent or is a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms; and U2 is absent or is a fluorinated group comprising 1 -10 carbon atoms and one or more fluorine atoms; wherein at least one of Ui and U2 is present;
X is a molecule that will recognize a cysteine protease; and
J is a reactive group that binds to a cysteine protease.
One aspect of the invention concerns a method for preventing and/or treating a caspase- mediated or cathepsin-associated disease or condition in a subject in need thereof, comprising administering to said subject an effective amount of a compound represented by any of the above molecules.
Another related aspect of the invention concerns the use of a compound represented by any of the above molecules for the manufacture of a medication for the prevention and/or treatment of caspase-mediated or cathepsin-associated diseases or conditions in a subject in need thereof.
One aspect of the invention concerns a method of treating excessive apoptosis or inflammation affected by caspase activity in a cell or a tissue, the method comprising: contacting the cell or tissue with an effective amount of one or more compounds represented by any of the above formulas.
A final aspect of the invention concerns the use of a compound represented by any of the above molecules to inhibit caspase or cathepsin activity in a cell-free system.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1: TFA-VAD(OMe)-FMK vs Z-VAD(OMe)-FMK vs Q-VD-OPH, Percent Inhibition of Caspase 3 at Varying Inhibitor Concentration. Competition Assay using active Caspase-3 and Ac- V AD- AFC (Enzo Lifesciences). Fluorescence kinetic reads performed with a Microplate Reader (M2e, Molecular Devices).
Figure 2: TFA-VAD(OMe)-FMK vs Z-VAD(OMe)-FMK vs Q-VD-OPH, Inhibition
Rate Constant Comparison. Competition Assay using active Caspase-3 and Ac- V AD- AFC (Enzo Lifesciences). Fluorescence kinetic reads performed with a Microplate Reader (M2e, Molecular Devices).
Figure 3: Structure of TFA-VAD(OMe)-FMK (aka Trifluoroacetyl-L-valyl-L-alanyl-L- aspartic acid methyl ester fluoromethyl ketone).
Figure 4: TFA-VAD(OMe)-FMK is more potent at inhibiting staurosporine-induced caspase activity compared to Z-VAD(OMe)-FMK and Q-VD(OMe)-FMK. Inhibitors (10 uM) were added to Jurkat cells (human T lymphocyte cell line) for 15 minutes. 1 uM Staurosporine (protein kinase inhibitor) was then added for 3.5 hours to induce apoptosis. After 3.5 hours, CAS-MAP active caspase labeling reagent (FAM-VAD(OMe)-FMK) was added for 20 minutes. Cells were then analyzed by flow cytometry. An increase in FAM-VAD-FMK fluorescence intensity correlates with caspase activity.
Figure 5: TFA-VAD(OMe)-FMK is more potent than Z-VAD(OMe)-FMK at inhibiting apoptosis. Jurkat cells were incubated with the indicated concentrations of TFA-VAD(OMe)- FMK or Z-VAD(OMe)-FMK for 15 minutes prior to stimulation with 1 μΜ Staurosporine for 4 hours, 5 μΜ Camptothecin (topoisomerase I inhibitor) for 4 hours or 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours. Cells were labeled with Annexin V - Alexa Fluor 488 and a cell impermeable DNA dye (SYTOX AADvanced) and analyzed by flow cytometry. % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. Data were normalized to no inhibitor samples (unstimulated = 0%, stimulated = 100%) and percent inhibition was calculated.
Figure 6: TFA-VAD(OMe)-FMK inhibits staurosporine-induced apoptosis after 24 hours in cell culture. Jurkat cells were incubated with 10 μΜ TFA-VAD(OMe)-FMK or 10 μΜ TFA-VAD(OMe)-FMK for 24 hours in RPMI 1640 media with 10% FBS. After 24 hours, cells were stimulated for 4 hours with 1 μΜ staurosporine to induce apoptosis followed by labeling with Annexin V - Alexa Fluor 488 and a cell impermeable DNA dye (SYTOX AADvanced). Stained cells were analyzed by flow cytometry. % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations.
Figure 7: TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit caspase-3/7 activity in Hep G2 cells (human hepatocyte carcinoma cell line). Hep G2 cells were incubated with the indicated concetrations of caspase inhibitor for 15 minutes prior to a 24 hour treatment with 2 μg/ml anti-TRAIL R2 agonist antibody to induce caspase activity. After 24 hours, a caspase-3/7 specific fluorescent substrate (MP39) was added to each sample in a duel function cell lysis/caspase activity buffer. After 2 hours of substrate incubation, fluorescence was determined using a fluorescence microplate reader. Relative Fluorescent Units were normalized to no inhibitor samples (no anti-TRAIL R2 antibody = 0%, + anti-TRAIL R2 antibody = 100%) and percent inhibition was calculated. Figure 8: TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit staurosporine-induced apoptosis in Jurkat cells. Jurkat cells were incubated with 5 μΜ of the indicated caspase inhibitor for 15 minutes prior to stimulation with 1 μΜ staurosporine for 4 hours. Cells were labeled with Annexin V - Alexa Fluor 488 and a cell impermeable DNA dye (SYTOX AADvanced) and analyzed by flow cytometry. % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. Data were normalized to no inhibitor samples (no staurosporine = 0%, + staurosporine = 100%) and percent inhibition was calculated.
Figure 9: TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA-
EVD-TPH and TFA-6E8D-TPH inhibit anti-TRAIL R2 antibody-induced apoptosis in Jurkat cells. Jurkat cells were incubated with the indicated concentrations of caspase inhibitor for 15 minutes prior to stimulation with 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours. Cells were labeled with Annexin V - Alexa Fluor 488 and a cell impermeable DNA dye (SYTOX AADvanced) and analyzed by flow cytometry. % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. Data were normalized to no inhibitor samples (no anti-TRAIL R2 antibody = 0%, + anti-TRAIL R2 antibody = 100%) and percent inhibition was calculated.
Figure 10. RAW 264.7 cells were incubated with TFA-FK-TPH, TFA-FR-TPH or E64d at the indicated concentrations for 1 hour prior to a 2 hour incubation with 1 μΜ BMV109. Cells were then collected, lysed in hypotonic lysis buffer and protein concentrations were determined. 50 μg of cell lysate was separated by SDS-PAGE on 15% Mini-PROTEAN TGX precast gels (Bio Rad). Gels were scanned using a Typhoon FLA 9500 (Cy5).
DETAILED DESCRIPTION
The present disclosure relates to cysteine protease inhibitors that covalently bind to cysteine proteases (e.g. active caspases or cathepsins), and methods of using such inhibitors to block caspase-mediated apoptosis, caspase-mediated inflammation, and cathepsin expression associated with any of the cathepsin related conditions mentioned herein. The present disclosure further relates to kits comprising the present cysteine protease inhibitors and instructions for their use.
Without being bound to any particular theory, it is believed that the presence of F in the compounds of the invention enhances cell permeability and or improves inhibitor-enzyme binding. This is because fluorine is a small and dense atom, only about 10% bigger in diameter than hydrogen and fluorine-containing molecules are hydrophobic.
Definitions
As used herein, the term "biological sample" refers to any type of material of biological origin, including but not limited to a blood sample, tissue sample, cell suspension, cellular extract, or tissue homogenate.
As used herein, the term "cysteine protease" includes enzymes that degrade proteins using a nucleophilic cysteine thiol. In one embodiment, the cysteine protease is a caspase or cysteine cathepsin. In one embodiment, the cysteine protease is a caspase. In one embodiment, the cysteine protease is a cysteine cathepsin.
As used herein, the term "zn vitro " refers to processes or procedures performed on a biological sample outside a living organism. For example, in vitro administration includes administering (i.e., delivering, applying, etc.) a cysteine protease inhibitor to a biological sample that is outside a living organism.
As used herein, the term "m vivo'" refers to processes or procedures performed inside a living, multicellular organism. For example, in vivo administration includes administering a cysteine protease inhibitor to a living subject (e.g., a mammal, such as a human).
As used herein, the term "incidence" refers to the occurrence rate, frequency of an event, or the quantifiable degree to which an event occurs.
As used herein, the term "incubating", when used with respect to incubating a sample with a cysteine protease inhibitor, refers to exposure conditions (e.g., time, temperature, pH, etc.) sufficient for the formation of caspase-inhibitor or cathepsin-inhibitor complexes.
As used herein, the term "N-terminal group" refers to a moiety attached to the N- terminal position of the recognition sequence of the cysteine protease inhibitor. The N-terminal group in the caspase inhibitors (and certain cathepsin inhibitors) of this invention is a
trifluoroacetyl (TFA) group.
As used herein, the term "C-terminal group" refers to a moiety attached to the C-terminal position of the recognition sequence of the cysteine protease inhibitor. The C-terminal group end of the molecule, in certain cathepsin inhibitors described in this invention, contains a
trifluoroacetyl (TFA) group.
As used herein, the term "reactive group that binds to a cysteine protease" includes groups that are capable of interacting with or reacting with the catalytic site of a cysteine protease.
In one embodiment, a reactive group is capable of interacting with or reacting with the catalytic site of a caspase or cysteine cathepsin. In one embodiment, a reactive group is capable of forming a covalent bond with a cysteine protease. In one embodiment, a reactive group is capable of forming a covalent bond with a caspase or cysteine cathepsin. In one embodiment, a reactive group is a leaving group that can be displaced to form a covalent bond. In one embodiment, for example, the reactive group can be FMK, PMK, OPH, or TPH. In one embodiment, for example, the reactive group can be a halogen atom, a substituted or unsubstituted phenol group, a substituted or unsubstituted benzoylate group, a substituted or unsubstituted BMK group, a substituted or unsubstituted FMK group, and a substituted or unsubstituted PMK group. In one embodiment, for example, the reactive group can be a halogen atom (e.g. F or CI) or a (C1 -C4) alkyl group that is substituted with one or more halogen atoms. In one embodiment, for example, the reactive group can be a portion of a cysteine protease inhibitor that covalently binds to the active catalytic site of a cysteine protease.
As used herein, the term "recognition sequence" refers to a portion of the cysteine protease inhibitors comprising a sequence of 1 to 8 natural or unnatural amino acids or synthetic analogs thereof, which is selective for one or more cysteine proteases.
As used herein, the term "synthetic analog" in regard to an amino acid refers to a (chemically) substituted natural amino acid, an unsubstituted unnatural amino acid, or a substituted unnatural amino acid.
As used herein, the term "unnatural amino acid" refers to an amino acid (or conformation thereof) not normally found in nature (i.e. not found in the genetic code of any organisms, not encoded into proteins). Synthetic analogs are a type of unnatural amino acid.
As used herein, the term "substituted," with respect to a group, means the group is substituted with one or more (e.g., 1 , 2, 3, 4 or 5) substituents independently selected from halo, cyano, nitro, carboxy, (C1-C4) alkyl, (C1-C4) haloalkyl, (C1-C4) alkoxy, (C] -C4) haloalkoxy, (Ci-C4) alkanoyl, (CrC4) alkoxycarbonyl, (CrC4) alkanoyloxy, amino, (CrC4) alkylamino, and ((C!-C4)alkyl)2 amino.
As used herein, the following abbreviations have the meanings given.
AOMK = acyloxymethyl ketone
BMK = benzoyloxymethyl ketone DE = L-aspartyl-L-glutamic acid
FK = phenylalyl lysine
FMK = fluoromethyl ketone
=
Figure imgf000012_0001
6E(OMe)8D(OMe) =
Figure imgf000012_0002
HD = L-histidyl-L-aspartic acid
IE = L-isoleucyl-L-glutamic acid
LAD = L-leucyl-L-alanyl-L-aspartic acid
LE = L-leucyl-L-glutamic acid
NMe = N-methyl
OMe = methyl ester
OPH = 2,6-difluoro substituted PMK
PMK = phenoxymethyl ketone
TD = L-threonyl-L-aspartic acid
TFA = trifluoroacetyl
TPH = 2,3,5,6-tetrafluoro substituted PMK
VAD = L-valyl-L-alanyl-L-aspartic acid VD = L-valyl-L-aspartic acid
WE = L-tryptophanyl-L-glutamic acid
YE = L-tyrosinyl-L-glutamic acid
Z = carbobenzyloxy
N-Terminal Group (Protecting Group)
The N-terminal group may serve to protect the recognition sequence during synthesis of a cysteine protease inhibitor. In at least one embodiment, an N-terminal protecting group may be present during synthesis of an intermediate precursor of a cysteine protease inhibitor, but may be removed and replaced with a different N-terminal moiety - i.e., the N-terminal group of a cysteine protease inhibitor intermediate may be different from the N-terminal group of a final cysteine protease inhibitor.
The N-terminal group on final caspase inhibitors and some final cysteine cathepsin inhibitors described in this invention is a trifluoroacetyl (TFA) group. In certain final cysteine cathepsin inhibitors described in this invention, the trifluoroacetyl (TFA) group is located on the C-terminal end of the Recognition Sequence. It is believed that a TFA group on the N-Terminal or C-Terminal position of a peptide based cysteine protease inhibitor enhances binding to the enzyme and/or enhances cell membrane permeability of the cysteine protease inhibitor. Recognition Sequence
Each recognition sequence comprises one or more natural or unnatural, synthetically modified amino acids and is able to bind to one or more caspases or cysteine cathepsins. In general, amino acids of the recognition sequence may be L, D, or D/L racemates. A recognition sequence may allow the cysteine protease inhibitor to target structurally similar caspases or cysteine cathepsins with the same or different affinities and kinetics. For instance, the recognition sequence VAD (valine-alanine-aspartic acid) is a poly-caspase inhibitor that binds to all or most known caspases (Garcia-Calvo et al., J. Biol. Chem. 273(49):32608-13 (1998)), and thus all of the disclosed reactive groups present in caspase inhibitors containing the VAD recognition sequence will covalently bind to all or most active caspases. Accordingly, in at least one embodiment, the caspase inhibitor is designed to react with multiple caspases to allow inhibition of all or most caspases. Similarly, the FK recognition sequence is designed to react with multiple cysteine cathepsins (B/L/S/X/Z). Accordingly, the FK containing cysteine cathepsin inhibitors described herein are considered "poly" cysteine cathepsin inhibitors.
In at least one other embodiment, the caspase inhibitor is designed to react selectively with caspase- 1, thus allowing for detection of inflammation in particular. For instance, caspase inhibitors containing the recognition sequence WEHD (SEQ ID NO:l) or YVAD (SEQ ID NO:2) will bind covalently to caspase-1 over other apoptosis-associated caspases.
In at least one other embodiment, the caspase inhibitor is designed to react with two caspases that have similar substrate selectivity. For instance, caspase inhibitors containing the recognition sequence DEVD (SEQ ID NO:3) will recognize and allow detection of both caspase-3 and caspase-7.
In at least one embodiment, the caspase inhibitor recognition sequence is selected from inhibitor recognition sequences listed in Table 1. Table 1 identifies well known recognition sequences of caspase inhibitors disclosed herein and their corresponding ability to selectively bind to all or most active caspases (i.e., poly-caspase), inflammation-related active caspases (e.g., caspase-1), or apoptosis-related active caspases (e.g., caspase-3/7 or caspase-8).
Table 1
Figure imgf000014_0001
In one embodiment, the molecule that will recognize a cysteine protease (i.e. the cysteine protease inhibitor recognition sequence) is selected from:
Figure imgf000015_0001
Examples of synthetic or "unnatural" amino acids include (but are not limited to):
Figure imgf000015_0002
In at least one embodiment, the cysteine cathepsin inhibitor recognition sequence is FK, FR, GGR (including synthetic analogs thereof). Reactive Group - Binding Mechanism to Active Caspase (Illustrative Example)
Following the administration of a caspase inhibitor, a multi-step binding mechanism results in the formation of a covalent bond between the reactive group and the -SH moiety of the cysteine residue in the active catalytic site of the caspase. According to at least one embodiment, the caspase inhibitor binds irreversibly and covalently to the caspase.
In at least one embodiment, the caspase inhibitors comprise a reactive group that enables the inhibitor to covalently bind to an active caspase. Typically, the reactive group includes a moiety that leaves as the reactive group reacts with the active caspase. The reactive group can be tailored to recognize and bind to specific types of caspases, such as caspases associated with apoptosis, caspases associated with inflammation, or caspases associated with both.
A representative example of the multi-step binding mechanism is illustrated below for caspase inhibitors that comprise a ketone that reacts with the cysteine residue in the catalytic site of an active caspase. This same general mechanism (nucleophilic attack on the electrophilic leaving group) applies to cysteine cathepsin inhibitors described in this invention. For the epoxide containing cysteine cathepsin inhibitors described herein, the epoxysuccinyl group irreversibly binds to an active thiol group on target cysteine cathepsins to form a thioether linkage.
Binding Mechanism of DEVD-FMK to Cysteine Residue in Catalytic Site of Active
Caspase
Formation of Thiohemiketal Intermediate I:
Figure imgf000016_0001
Formation of Three-Membered Sulfonium Intermediate II:
Figure imgf000017_0001
Formation of Stable Covalent Bond:
Figure imgf000017_0002
As shown above, the three-membered sulfonium Intermediate II rearranges to yield the final thioether adduct.
Reactive Group - Binding Mechanism of Epoxide Containing Inhibitor to Cysteine Cathepsin
Figure imgf000017_0003
General Structure of Cysteine Protease Inhibitors
In one embodiment the caspase inhibitors (and select cysteine cathepsin inhibitors) of the present disclosure have the following general structure: (U)-X-J-(U), where U must be present on at least one end of the molecule and may be attached directly or indirectly (i.e. via linker) to the C-terminal and/or N-terminal end of the molecule, and where U is a fluorinated group or perfluoroalkyl group comprising 1-10 carbon atoms and one or more fluorine atoms (e.g. a trifluoroacetyl (TFA) group); X is any molecule that will recognize a cysteine protease (e.g. a peptide-based caspase or cysteine cathepsin recognition sequence containing 1-8 amino acids or synthetic analogs thereof), and J is any reactive group that binds to a caspase or cysteine cathepsm (e.g. a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy- methyl ketone a.k.a. "TPH" or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH"), an acyloxy- methyl ketone a.k.a. "AOMK" or an epoxide).
In one embodiment the caspase inhibitors of the present disclosure are further described by the following formula:U-X-NH-CH(R)-CO-CH2-J,where U is any fluorinated group or perfluoroalkly group (e.g. a trifluoroacetyl (TFA) group), X is any molecule that will recognize an active caspase (e.g. a peptide having 1-8 amino acids or synthetic analogs thereof), R is CH2- C02-CH3 for live cells and in vivo applications or CH2-C02-H for cell-free systems, and J is any molecule that will react with active caspases; for example, a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy-methyl ketone a.k.a. "TPH" or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH"), an acyloxy-methyl ketone a.k.a. "AOMK" or an epoxide).
In this general structure, U comprises the N-terminal group, X-NH-CH(R)-CO-CH2 comprises the recognition sequence, and J comprises the reactive group.
In one embodiment, X is selected from one or more naturally occurring amino acids, one or more synthetic amino acids and combinations thereof. X may be one or more amino acids selected from alanine, aspartic acid, glutamic acid, histidine, glycine, arginine, lysine, methionine, proline, isoleucine, phenylalanine, leucine, threonine, tryptophan, valine, tyrosine, glutamine, serine, pyrrolysine, selenocysteine, norvaline, norleucine and synthetic analogs thereof (where applicable).
In one embodiment, J is capable of binding at least one caspase selected from caspase- 1 , caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase- 10, caspase- 1 1, caspase- 12, caspase- 13 and caspase- 14. J may be selected from BMK, FMK, PMK, OPH, TPH and AOMK.
In one embodiment, J is capable of binding at least one caspase selected from caspase- 1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase- 10, caspase- 1 1, caspase- 12, caspase- 13 and caspase- 14. J may be selected from FMK, PMK, OPH, TPH and AOMK. In one embodiment, J is capable of binding to at least one cysteine cathepsin selected from Cathepsins B, C, F, H, K, L, O, S, W, X/Z. J may be selected from FMK, PMK, OPH, TPH and AOMK.
In one embodiment, J is selected from a halogen, a phenol group, a benzoylate group, a BMK group, an FMK group, and a PMK group, in which the groups mentioned herein may be substituted or unsubstituted.
In one embodiment, J is selected from BMK, FMK, and PMK. In at least one embodiment, the J halogen is F, CI, or Br. In at least one embodiment, the J phenol is a compound of Formula A:
Formula A
Figure imgf000019_0001
wherein X1? X2, X3, X4, and X5 is each individually selected from H, F, CI, alkyl, aryl, aralkyl, amino, nitro, and carboxy. In one embodiment, at least one of Xj, X2, X3, X , and X5 is H. In at least one embodiment, alkyl is C1-10 alkyl, for example, Ci-6 alkyl. In at least one embodiment, the J benzoylate is a compound of Formula B:
Formula B
Figure imgf000019_0002
wherein X1? X2, X3, X4, and X5 is each individually selected from H, F, CI, alkyl, aryl, aralkyl, amino, nitro, or carboxy. In one embodiment, at least one of X], X2, X3, X4, and X5 is H. In at least one embodiment, alkyl is C1-10 alkyl, for example, Ci-6 alkyl.
In one embodiment, the cysteine protease inhibitor has a molecular weight of about 300- 1500 Daltons.
The cysteine protease inhibitors are typically cell permeant (i.e., exhibit good cell membrane permeability) and can typically selectively target cysteine proteases (i.e. caspases and cysteine cathepsins) of interest inside the cells of a living organism or a biological sample.
In at least one embodiment, the cysteine protease inhibitors do not undergo facile metabolism, and possess a long half-life (e.g., more than 6 hours) throughout the life of the permeated cell.
Additionally, since the cysteine protease inhibitors bind to caspases as illustrated in the representative binding mechanisms shown above, each cysteine protease inhibitor forms a metabolite having the formula U-X-NH-CH(R)-CO-CH2-S-Cys-Enzyme, wherein U, X, and R are as defined above.
Representative Examples of Caspase Inhibitors
An example of caspase inhibitors of the present disclosure includes, but is not limited to TFA-VAD(OMe)-FMK:
Figure imgf000020_0001
-VD(OMe)-FMK
Figure imgf000020_0002
TFA-VAD-FMK
Figure imgf000020_0003
Figure imgf000021_0001
Figure imgf000021_0002
TFA-VADOMe)-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000021_0003
Figure imgf000021_0004
TFA-VAD-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000022_0001
TFA-(2-Oxoacetamido)(Propanamido)-4-Oxo-5-(2,3,5,6-Tetrafluorophenoxy) Pentanoic Acid
Figure imgf000022_0002
TFA-Asp-3,4 Difluorophenylalanine-Val-Asp-2,3,5,6 Tetrafluorophenoxymethyl Ketone
Figure imgf000022_0003
TFA-Asp-Pentafluorophenylalanine-Val-Asp-2,3,5,6 Tetrafluorophenoxymethyl Ketone
Figure imgf000022_0004
TFA-EVD-2,355,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000023_0001
TFA-E(OMe)VD(OMe)-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000023_0002
TFA-6E8D-2,3,5,6 Tetrafluorophenoxymethyl Ketone
Figure imgf000023_0003
TFA-6E(OMe)8D(OMe)-2,3,5,6 Tetrafluorophenoxymethly Ketone
Figure imgf000023_0004
Representative Examples of Cysteine Cathepsin Inhibitors
Examples of cysteine cathepsin inhibitors of the present disclosure include, but are not limited to:
Figure imgf000024_0001
Figure imgf000024_0002
(R,R at the epoxide) Administration or Delivery of Cysteine Protease Inhibitors
Examples of organs or targets applicable to the use of cysteine protease inhibitors include, but are not limited to: eye, breast, heart, brain and central nervous system (CNS), kidneys, lungs, liver, skin, pancreas, skeletal system, connective tissue (e.g., joints), stomach, upper gastrointestinal tract, lower gastrointestinal tract, circulatory system (e.g., blood), lymphatic system, sexual organs (male and female), prostate, embryologic tissue, muscular system, and gallbladder.
In at least one embodiment, the cysteine protease inhibitor is delivered in vitro to a biological sample (e.g., a blood sample, tissue sample, cell suspension, cellular extract, or tissue homogenate) by direct application of the inhibitor to the sample. Given that the cysteine protease inhibitors exhibit good cell permeability, there is no need to use additional reagents to facilitate the entry of the inhibitors into cells. In one instance, the cysteine protease inhibitor is reconstituted in DMSO, further diluted in phosphate buffered saline (PBS) or cell culture media and applied directly to cells in a cell culture dish. Upon application, the cysteine protease inhibitor is allowed to incubate with the cells under the conditions sufficient for the formation of caspase-inhibitor complexes.
In at least one other embodiment, the cysteine protease inhibitor is administered in vivo to a subject (e.g., animal or human) intravenously, intraperitoneally, intramuscularly, subcutaneously, topically, and/or by direct application to a target organ. The cysteine protease inhibitor is diluted with a suitable excipient (in some cases a pharmaceutically acceptable excipient) and administered in an effective amount, which is an amount that is sufficient to provide meaningful results with respect to the intended purpose - e.g., therapeutic, drug development, etc. Suitable excipients include, but are not limited to, adhesives, binders, bulking agents, carriers, colors, diluents, disintegrating agents, fillers, glidants, granulating agents, lubricating agents, polymers, preservatives, wetting agents, and combinations thereof. One or more excipients may be selected from sucrose, lactose, cellulose, methyl cellulose, gelatin, polyvinylpyrrolidone, polyethylene glycol and water. Kits
In general, the kits of the present disclosure are used for blocking apoptotic activity and/or conditions associated with inflammatory activity in a biological sample. The kit may comprise one or more cysteine protease inhibitors. The kit may further include packaging materials with instructions for using the components of the kit, such as how to use the cysteine protease inhibitors provided in the kit, storage conditions, etc. Components of the kit may be provided in separate containers (e.g., vials) or combined.
Embodiments
In one aspect, the invention relates to a kit containing instructions for use and at least one cysteine protease inhibitor compound of the following formula: (U)-X-J-(U), where at least one U must be present and where U may be attached either directly or indirectly (i.e. via linker) to the C-terminal or N-terminal end of the molecule, and where U is a fluorinated group or perfluoroalkyl group comprising 1-10 carbon atoms and one or more fluorine atoms (e.g. a trifluoroacetyl (TFA) group); X is any molecule that will recognize a cysteine protease (e.g. a peptide-based caspase or cysteine cathepsin recognition sequence containing 1-8 amino acids or synthetic analogs thereof), and J is any reactive group that binds to a caspase or cysteine cathepsin (e.g. a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy- methyl ketone a.k.a. "TPH" or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH"), an acyloxy- methyl ketone a.k.a. "AOMK" or an epoxide).
In another aspect, the invention relates to a kit containing instructions for use and at least one caspase inhibitor compound of the following formula: U-X-NH-CH(R)-CO-CH2-J, where U is any fluorinated group or perfluoroalkly group (e.g. a trifluoroacetyl (TFA) group), X is any molecule that will recognize an active caspase (e.g. a peptide having 1-8 amino acids or synthetic analogs thereof), R is CH2-C02-CH3 for live cells and in vivo applications or CH2- C02-H for cell-free systems, and J is any molecule that will react with active caspases, e.g. a halo-methyl ketone such as fluoro-methyl ketone (FMK), a phenoxy-methyl ketone (PMK), or a substituted phenoxy-methyl ketone (such as a 2,3,5,6 tetrafluoro phenoxy-methyl ketone ("TPH") or a 2,6 difluoro phenoxy-methyl ketone a.k.a. "OPH"), an acyloxy-methyl ketone a.k.a. "AOMK" or an epoxide). In another aspect, the "X" for the caspase or cysteine cathepsin inhibitor comprises at least one amino acid selected from alanine, aspartic acid, glutamic acid, histidine, glycine, arginine, lysine, methionine, proline, isoleucine, phenylalanine, leucine, threonine, tryptophan, valine, tyrosine, glutamine, serine, pyrrolysine, selenocysteine, norvaline, norleucine and synthetic analogs thereof (where applicable).
In another aspect, the compound is selected from the group consisting of:
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
TFA-WEHD-FMK TFA-IETD-FMK TFA-DEVD-FMK
TFA-WEHD-PMK TFA-IETD-PMK TFA-DEVD-PMK
TFA-WEHD-OPH TFA-IETD-OPH TFA-DEVD-OPH
TFA-WEHD-TPH TFA-IETD-TPH TFA-DEVD-TPH
TFA-WEHD-AOMK TFA-IETD-AOMK TFA-DEVD-AOMK
TFA-LEHD-FMK TFA-LETD-FMK TFA-VDVAD-FMK
TFA-LEHD-PMK TFA-LETD-PMK TFA-VDVAD-PMK
TFA-LEHD-OPH TFA-LETD-OPH TFA-VDVAD-OPH
TFA-LEHD-TPH TFA-LETD-TPH TFA-VDVAD-TPH TFA-LEHD-AOMK TFA-LETD-AOMK TFA-VDVAD-AOMK
TFA-6E8D-FMK TFA-EVD-FMK
TFA-6E8D-PMK TFA-EVD-PMK
TFA-6E8D-OPH TFA-EVD-OPH
TFA-6E8D-TPH TFA-EVD-TPH
TFA-6E8D-AOMK TFA-EVD-AOMK
In another aspect, the compound is selected from the group consisting of:
TFA-VAD(OMe)-FMK TFA-YVAD(OMe)-FMK TFA-WE(OMe)HD(OMe)-FMK TFA-VAD(OMe)-PMK TFA-YVAD(OMe)-PMK TFA-WE(OMe)HD(OMe)-PMK TFA-VAD(OMe)-OPH TFA-YVAD(OMe)-OPH TFA-WE(OMe)HD(OMe)-OPH TFA-VAD(OMe)-AOMK TFA-YVAD(OMe)-AOMK TFA-WE(OMe)HD(OMe)-AOMK TFA-IE(OMe)TD(OMe)-FMK TFA-D(OMe)E(OMe)VD(OMe)-FMK
TFA-IE(OMe)TD(OMe)-PMK TFA-D(OMe)E(OMe)VD(OMe)-PMK
TFA-IE(OMe)TD(OMe)-OPH TFA-D(OMe)E(OMe)VD(OMe)-OPH
TFA-IE(OMe)TD(OMe)-AOMK TFA-D(OMe)E(OMe)VD(OMe)-AOMK
TFA-LE(OMe)HD(OMe)-FMK TFA-LE(OMe)TD(OMe)-FMK
TFA-LE(OMe)HD(OMe)-PMK TFA-LE(OMe)TD(OMe)-PMK
TFA-LE(OMe)HD(OMe)-OPH TFA-LE(OMe)TD(OMe)-OPH
TFA-LE(OMe)HD(OMe)-AOMK TFA-LE(OMe)TD(OMe)-AOMK
TFA-VD(OMe)VAD(OMe)-FMK TFA-VD(OMe)-FMK
TFA-VD(OMe)VAD(OMe)-PMK TFA-VD(OMe)-PMK
TFA-VD(OMe)VAD(OMe)-OPH TFA-VD(OMe)-OPH
TFA-VD(OMe)VAD(OMe)-AOMK TFA-VD(OMe)-AOMK
TFA-VAD-FMK TFA-YVAD-FMK TFA-WEHD-FMK
TFA-VAD-PMK TFA-YVAD-PMK TFA-WEHD-PMK
TFA-VAD-OPH TFA-YVAD-OPH TFA-WEHD-OPH
TFA-VAD-AOM TFA-YVAD-AOMK TFA-WEHD-AOMK
TFA-IETD-FMK TFA-DEVD-FMK
TFA-IETD-PMK TFA-DEVD-PMK
TFA-IETD-OPH TFA-DEVD-OPH TFA-IETD-AOMK TFA-DEVD-AOMK
TFA-LEHD-FMK TFA-LETD-FMK
TFA-LEHD-PMK TFA-LETD-PMK
TFA-LEHD-OPH TFA-LETD-OPH
TFA-LEHD-AOMK TFA-LETD-AOM
TFA-VDVAD-FMK TFA-VD-FMK
TFA-VDVAD-PMK TFA-VD-PMK
TFA-VDVAD-OPH TFA-VD-OPH
TFA-VDVAD-AOMK TFA-VD-AOMK
and pharmaceutically acceptable derivatives thereof.
In another aspect, the compound is selected from the group consisting of:
TFA-VAD(OMe)-FMK
Figure imgf000031_0001
TFA-VD(OMe)-FMK
Figure imgf000031_0002
TFA-VAD-FMK
Figure imgf000031_0003
TFA-VD-FMK
Figure imgf000032_0001
TF A- VD(OMe)-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000032_0002
TFA-VAD OMe)-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000032_0003
TF A- VD-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000032_0004
TFA-VAD-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000032_0005
TFA-EVD-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000033_0001
TFA-E(OMe)VD(OMe)-2,3,5,6-Tetrafluorophenoxymethyl Ketone
Figure imgf000033_0002
TFA-6E8D-2,3,5,6 Tetrafluorophenoxymethyl Ketone
Figure imgf000033_0003
TFA-6E(OMe)8D(OMe)-2,3,5,6 Tetrafluorophenoxymethly Ketone
Figure imgf000033_0004
TFA-(2-Oxoacetamido)(Tropanamido)-4-Oxo-5-(2,3,5,6-Tetrafluorophenoxy) Pentanoic Acid
Figure imgf000034_0001
TFA-Asp-3,4 Difluorophenylalanine-Val-Asp-2,3,5,6 Tetrafluorophenoxymethyl Ketone
Figure imgf000034_0002
TFA-Asp-PentafluorophenyIalanine-VaI-Asp-2,3,5,6 Tetrafluorophenoxymethyl Ketone
Figure imgf000034_0003
and pharmaceutically acceptable derivatives thereof.
In another embodiment, the compound is selected from the group consisting of:
TFA-FK-FMK TFA-FR-FMK TFA-GGR-FMK
TFA-FK-PMK TFA-FR-PMK TFA-GGR-PMK
TFA-FK-OPH TFA-FR-OPH TFA-GGR-OPH
TFA-FK-TPH TFA-FR-TPH TFA-GGR-TPH
TFA-FK-AOMK TFA-FR-AOMK TFA-GGR-AOMK
and pharmaceutically acceptable derivatives thereof.
In another embodiment, the compound contains an epoxide based "J" reactive group and is selected from the group consisting of:
Figure imgf000035_0001
and pharmaceutically acceptable derivatives thereof.
In another embodiment, the compound contains at least one cathepsin inhibitor and is selected from the group consisting of:
Figure imgf000035_0002
Figure imgf000035_0003
Figure imgf000036_0001
Figure imgf000036_0002
harmaceutically acceptable derivatives thereof.
In another embodiment, the present invention relates to a composition comprising a caspase inhibitor or cysteine cathepsin inhibitor and an excipient (which may be selected from sucrose, lactose, cellulose, gelatin, polyvinylpyrrolidone, trehalose, cyclodextrin, hyaluronic acid, polyethylene glycol, DMSO and water.
In another embodiment, the present invention relates to a method of inhibiting apoptosis and/or inflammation in a living organism by administering in vivo a caspase inhibitor or cathepsin inhibitor to the living organism.
In another embodiment, the present invention relates to a method of inhibiting apoptosis and/or inflammation in a cell population by administering in vitro a caspase inhibitor or cathepsin inhibitor to a biological sample and incubating the sample with the inhibitor under conditions sufficient to form caspase-inhibitor complexes. The biological sample may be selected from a blood sample, tissue sample, cell suspension, cellular extract, or tissue homogenate.
In another embodiment, the compound is a compound of formula (la): UrX-J (la).
In another embodiment, the compound is a compound of formula (lb):
X-J-U2 (lb). In another embodiment, the compound is a compound of formula (Ic): CF3-C(=0)-X-J (Ic).
In another embodiment, X is a molecule that will recognize a caspase or cysteine cathepsin.
In another embodiment, X is a peptide that contains 1-8 amino acids.
In another embodiment, X is a peptide that contains 2-5 amino acids.
In another embodiment, X is a peptide selected from the group consisting of: VD, VAD, EVD, D-3-V-D, L-E-H-D (SEQ ID NO:9), L-E-T-D (SEQ ID NO: 10), D-E-V-D (SEQ ID NO:3), D-E-P-D (SEQ ID NO:7), D-29-V-D, D-34-V-D, 26-34-V-D, 26-3-V-D, 26-E-V-D, 31- E-T-D, 31-E-23-D, 29-E-T-D, 6-E-8-D, D-E-1 1-D, D-30-11-D, D-30-V-D, P-L-A-D (SEQ ID NO:8), I-L-A-D (SEQ ID NO:l 1), I-L-38-D, I-F-P-D (SEQ ID NO:12), D-3-V-D, D-34-V-D, 31-E-23-D, and P-L-A-D (SEQ ID NO:8), wherein the numbers 3, 6, 8, 1 1, 23, 26, 29, 30, 31, 34, and 38 represent the following structures:
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
see Berger, A. B., et al., 2006, Mol. Cell 23, 509-21.
In another embodiment, J is selected from the group consisting of AMOK, BMK, FMK, OPH, PMK, and TPH.
In another embodiment, J is selected from the group consisting of AMOK, OPH, PMK, and TPH.
In another embodiment, J is TPH.
In another embodiment, the compound is selected from the group consisting of: TFA- EVD-TPH; TFA-6E8D-TPH; TFA-VAD(OMe)-TPH; TF A- VD(OMe)-TPH ; TFA-FK-TPH; and TFA-F -TPH.
In another embodiment, the compound is a compound of formula (Id): (U)-X-J-(U) (Id)
wherein:
U is present on at least one end of the molecule and consists of a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms;
X is any molecule that will recognize a cysteine protease; and
J is any reactive group that binds to a caspase or cysteine cathepsin.
In another embodiment, U is a trifluoroacetyl (TFA) group that may be connected directly or indirectly (i.e. via linker) to either the C-terminal end or to the N-terminal end J group.
In another embodiment, the compound is a compound of formula (Ie): (U)-X-NH-CH(R)-CO-CH2-J(U) (Ie)
wherein:
U is a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms X is a peptide-based caspase recognition sequence comprising 1-8 amino acids; R is -CH2C02CH3, -CH2C02H; and
J is any reactive group that binds to a caspase.
In another embodiment, U is a trifluoroacetyl (TFA) group that may be connected directly or indirectly (i.e. via linker) to either the C-terminal end or to the N-terminal end J group.
In another embodiment, X comprises at least one amino acid selected from alanine, aspartic acid, glutamic acid, histidine, glycine, arginine, lysine, methionine, proline, isoleucine, phenylalanine, leucine, threonine, tryptophan, valine, tyrosine, glutamine, serine, pyrrolysine, selenocysteine, norvaline, norleucine and synthetic analogs thereof (where applicable).
In another embodiment, X comprises VAD(OMe), VD(OMe), VAD, VD,
E(OMe)VD(OMe), EVD, 6E8D, 6E(OMe)8D(OMe), FK, FR, GGR, WE(OMe)HD(OMe), IE(OMe)TD(OMe), D(OMe)E(OMe)VD(OMe), LE(OMe)HD(OMe), LE(OMe)TD(OMe), YVAD(OMe), VD(OMe)VAD(OMe) or any of the following: Asp-3,4 Difluorophenylalanine- Val-Asp, Asp-Pentafluorophenylalanine-Val-Asp, (2-Oxoacetamido)(Propanarnido)-4-Oxo- Pentanoic Acid, (Oxiran-2-yl) Carbonyl-L-Leucyl-3-(p-Hydroxyphenyl) Ethylamide.
In another embodiment, X is VAD(OMe), VD(OMe), VAD, VD, E(OMe)VD(OMe), EVD, 6E8D, 6E(OMe)8D(OMe), FK, FR, GGR, WE(OMe)HD(OMe), IE(OMe)TD(OMe), D(OMe)E(OMe)VD(OMe), LE(OMe)HD(OMe), LE(OMe)TD(OMe), YVAD(OMe),
VD(OMe)VAD(OMe) or any of the following: Asp-3,4 Difluorophenylalanine- Val-Asp, Asp- Pentafluorophenylalanine- Val-Asp, (2-Oxoacetamido)(Propanamido)-4-Oxo-Pentanoic Acid, (Oxiran-2-yl) Carbonyl-L-Leucyl-3-(p-Hydroxyphenyl) Ethylamide.
In another embodiment, J is any molecule that will react with active cysteine proteases, e.g.a halomethyl ketone (such as CMK, FMK), a substituted or unsubstituted phenoxymethyl ketone (PMK), an acyloxymethyl ketone (AOMK), or an epoxide.
In another embodiment, the compound is selected from:
TFA-VAD(OMe)-FMK TFA-YVAD(OMe)-FMK TFA-WE(OMe)HD(OMe)-FMK TFA-VAD(OMe)-PMK TFA-YVAD(OMe)-PMK TFA-WE(OMe)HD(OMe)-PMK TFA-VAD(OMe)-OPH TFA-YVAD(OMe)-OPH TFA-WE(OMe)HD(OMe)-OPH TFA-VAD(OMe)-TPH TFA-YVAD(OMe)-TPH TFA-WE(OMe)HD(OMe)-TPH TFA-VAD(OMe)-AOMK TFA-YVAD(OMe)-AOMK TFA-WE(OMe)HD(OMe)-AOMK TFA-IE(OMe)TD(OMe)-FMK TFA-D(OMe)E(OMe)VD(OMe)-FMK
TFA-IE(OMe)TD(OMe)-PMK TFA-D(OMe)E(OMe)VD(OMe)-PMK TFA-IE(OMe)TD(OMe)-OPH TFA-D(OMe)E(OMe)VD(OMe)-OPH
TFA-IE(OMe)TD(OMe)-TPH TFA-D(OMe)E(OMe)VD(OMe)-TPH
TFA-IE(OMe)TD(OMe)-AOMK TFA-D(OMe)E(OMe)VD(OMe)-AOMK
TFA-LE(OMe)HD(OMe)-FMK TFA-LE(OMe)TD(OMe)-FMK TFA-
TFA-LE(OMe)HD(OMe)-PMK TFA-LE(OMe)TD(OMe)-PMK TFA-EVD-PMK
TFA-LE(OMe)HD(OMe)-OPH TFA-LE(OMe)TD(OMe)-OPH TFA-EVD-OPH
TFA-LE(OMe)HD(OMe)-TPH TFA-LE(OMe)TD(OMe)-TPH TFA-EVD-TPH
TFA-LE(OMe)HD(OMe)-AOMK TFA-LE(OMe)TD(OMe)-AOMK TFA-EVD-AOMK
TFA-VD(OMe)VAD(OMe)-FMK TFA-VD(OMe)-FMK TFA-E(OMe)VD(OME)- FMK
TFA-VD(OMe)VAD(OMe)-PMK TFA-VD(OMe)-PMK TFA-E(OMe)VD(OMe)- PMK
TFA-VD(OMe)VAD(OMe)-OPH TFA-VD(OMe)-OPH TFA-E(OMe)VD(OMe)- OPH
TFA-VD(OMe)VAD(OMe)-TPH TFA-VD(OMe)-TPH TFA-E(OMe)VD(OMe)- TPH
TFA-VD(OMe)VAD(OMe)-AOMK TFA-VD(OMe)-AOMK TFA-E(OMe)VD(OMe)- AOMK
TFA-VAD-FMK TFA-VD-FMK TFA-6E8D-FMK TFA-6E(OMe)8D(OMe)- FMK
TFA-VAD-PMK TFA-VD-PMK TFA-6E8D-PMK TFA-6E(OMe)8D(OMe)- PMK
TFA-VAD-OPH TFA-VD-OPH TFA-6E8D-OPH TFA-6E(OMe)8D(OMe)- OPH
TFA-VAD-TPH TFA-VD-TPH TFA-6E8D-TPH TFA-6E(OMe)8D(OMe)- TPH
TFA-VAD-AOMK TFA-VD-AOMK TF A-6E8 D- AOMK TFA-6E(OME)8D(OMe)-
AOMK
TFA-GGR-FMK TFA-FK-FMK TFA-FR-FMK
TFA-GGR-PMK TFA-FK-PMK TFA-FR-PMK
TFA-GGR-OPH TFA-FK-OPH TFA-FR-OPH
TFA-GGR-TPH TFA-FK-TPH TFA-FR-TPH TFA-GGR-AOMK TFA-FK-AOMK TFA-FR-AOMK and the following compounds:
Figure imgf000042_0001
Figure imgf000043_0001
In another embodiment, the compound is a compound of formula (If):
CF3-C(=0)-X-THP (If)
wherein X is a peptide that will recognize a caspase or cysteine cathepsin.
In another embodiment, the compound is a compound of formula (If):
CF3-C(=0)-X-THP (If)
wherein X is a peptide that contains 1-8 amino acids.
In another embodiment, the compound is a compound of formula (If):
CF3-C(=0)-X-THP (If)
wherein X is a peptide that contains 2-5 amino acids.
In another embodiment, the compound is a compound of formula (If):
CF3-C(=0)-X-THP (If)
wherein X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V- D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E-8D(OMe), V-A-D(OMe). V-D, V-D(OMe), F-K, F-R,VAD, EVD, D-3-V-D, L-E-H-D (SEQ ID NO:9), L-E-T-D (SEQ ID NO: 10), D-E-V-D (SEQ ID NO:3), D-E-P-D (SEQ ID NO:7), D-29-V-D, D-34-V-D, 26-34-V- D, 26-3-V-D, 26-E-V-D, 31-E-T-D, 31 -E-23-D, 29-E-T-D, 6-E-8-D, D-E-l 1-D, D-30-1 1 -D, D- 30-V-D, P-L-A-D (SEQ ID NO:8), I-L-A-D (SEQ ID NO:l 1), I-L-38-D, I-F-P-D (SEQ ID NO: 12), D-3-V-D, D-34-V-D, 31-E-23-D, and P-L-A-D (SEQ ID NO:8), wherein the numbers 3, 6, 8, 1 1, 23, 26, 29, 30, 31, 34, and 38 represent the following structures:
Figure imgf000044_0001
43
Figure imgf000045_0001
In another embodiment, X is a peptide selected from the group consisting of:
E(OMe)-V-D, E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E- 8D(OMe), V-A-D(OMe). V-D, V-D(OMe), F-K, F-R,VAD, EVD, and 6-E-8-D.
In another embodiment, X is a peptide selected from the group consisting of:
E(OMe)-V-D, E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E- 8D(OMe), V-A-D(OMe). V-D, V-D(OMe), VAD, EVD, and 6-E-8-D.
In another embodiment, X is a peptide selected from the group consisting of:
F-K and F-R. In another embodiment, J is acyloxymethyl, benzoyloxymethyl, fluoromethyl, 2,6- difluorophenoxymethyl, phenoxymethyl, or 2,3,5,6-tetrafluorophenoxymethyl, which form AMOK, BMK, FMK, OPH, PMK, or THP, respectively, when attached to the carboxy carbonyl group of X in a compound of the invention.
In another embodiment, a pharmaceutical composition is provided that comprises a compound of the invention and a pharmaceutically acceptable excipient, and optionally a therapeutic agent. In another embodiment, the excipient comprises sucrose, lactose, cellulose, gelatin, polyvinylpyrrolidone, trehalose, cyclodextrin, hyaluronic acid, polyethylene glycol or water. In another embodiment, the therapeutic agent is a cancer-targeted chemotherapeutic agent.
In another embodiment, a method for inhibiting a cysteine protease in vitro or in vivo is provided that comprises contacting the cysteine protease with a compound of the invention.
In another embodiment, a method for inhibiting a cysteine protease in vitro or in vivo is provided that comprises contacting the caspase with a compound of the invention. In another embodiment, the compound inhibits the cysteine protease by forming an irreversible covalent bond to the active site of a cysteine protease.
In another embodiment, a method for treating a disease or condition associated with an increase in cellular apoptosis and/or inflammation in a subject (e.g. animal or human) is provided that comprises administering to the subject a compound of the invention. In another embodiment, the disease or condition is myocardial infarction, stroke, traumatic brain injury, spinal atrophy, auto-immune diseases (e.g. Alzheimer's), fulminant liver destruction, endotoxic shock, sepsis, septic shock, liver disease such as chronic hepatitis (including virus-related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH"), pancreatitis, arthritis, viral infection, metabolic disease, cancer, implant or transplant rejection,
neurodegenerative diseases (e.g. multiple sclerosis), pulmonary fibrosis, cardiac fibrosis, renal fibrosis, liver fibrosis and cirrhosis or ototoxicity.
In another embodiment, a method for inhibiting apoptosis and/or inflammation
(including diseases or conditions associated with apoptosis and/or inflammation) in a subject (e.g. animal or human) is provided that comprises administering to the subject a compound of the invention.
In another embodiment, a method for inhibiting apoptosis and/or inflammation in a cell population is provided that comprises administering in vitro a compound of the invention to a biological sample to provide a resulting sample, and incubating the resulting sample under conditions sufficient to form caspase-inhibitor or cysteine cathepsin-inhibitor complexes. In another embodiment, the biological sample comprises blood sample, tissue, a cell suspension, a cellular extract, or a tissue homogenate.
In another embodiment, a method for preventing and/or treating a caspase-mediated or cysteine cathepsin-associated disease or condition in an subject (e.g. animal of human), is provided that comprises administering to the subject a compound of the invention.
In another embodiment, a kit comprising:
1 ) a compound of the invention; and
2) instructions for using the compound to inhibit a cysteine protease or to treat a cysteine protease-mediated disease or condition is provided.
In another embodiment, a kit comprising:
1) a compound of the invention; and
2) instructions for using the compound to inhibit a caspase or to treat a caspase- mediated disease or condition or a cysteine cathepsin-associated disease or condition.
In another embodiment, a method of inhibiting caspase or cysteine cathepsin activity in a cell-free system, is provided that comprises adding a compound of the invention to the purified caspases.
In another embodiment, the compounds of the invention (e.g. the compounds of formula
I, la, lb, Ic, Id, and Ie) exclude the following compounds:
4-18F-B-GVAD(OMe)-BM ,
4-18F-B-GVAD(OMe)-FMK,
4-18F-B-GVAD(OMe)-PMK,
780-G-F6V-AD(OMe)-BMK,
780-G-F6V-AD(OMe)-FMK,
780-G-F6V-AD(OMe)-PMK,
780-G-F6V-AD-BMK,
780-G-F6V-AD-FMK,
780-G-F6V-AD-PMK,
ABzC-G-F6V-AD(OMe)-BMK,
ABzC-G-F6V-AD(OMe)-FMK, ABzC-G-F6V-AD(OMe)-PMK,
ABzC-G-F6V-AD-BMK,
ABzC-G-F6V-AD-FMK,
ABzC-G-F6V-AD-PMK,
BODIPY-FL-G-F6V-AD(OMe)-BMK,
BODIPY-FL-G-F6V-AD(OMe)-FMK,
BODIPY-FL-G-F6V-AD(OMe)-PMK,
BODIPY-FL-G-F6V-AD-BMK,
BODIPY-FL-G-F6V-AD-FMK,
BODIPY-FL-G-F6V-AD-PMK,
BODIPY-FL-GVAD(OMe)-BMK,
BODIPY-FL-GVAD(OMe)-FMK,
BODIPY-FL-GVAD(OMe)-PMK,
BODIPY-FL-GVAD-BMK,
BODIPY-FL-GVAD-FMK,
BODIPY-FL-GVAD-PMK,
FAM-G-F6V-AD(OMe)-BMK,
FAM-G-F6V-AD(OMe)-FMK
FAM-G-F6V-AD(OMe)-PMK,
FAM-G-F6V-AD-BMK,
FAM-G-F6V-AD-FMK,
FAM-G-F6V-AD-PMK,
N-AE-G-F6V-AD(OMe)-BMK,
N-AE-G-F6V-AD(OMe)-FMK,
N-AE-G-F6V-AD(OMe)-PMK,
N-AE-G-F6V-AD-BMK,
N-AE-G-F6V-AD-FMK,
N-AE-G-F6V-AD-PMK,
N-AM-G-F6V-AD(OMe)-BMK,
N-AM-G-F6V-AD(OMe)-FMK,
N-AM-G-F6V-AD(OMe)-PMK,
N-AM-G-F6V-AD-BMK, N-AM-G-F6V-AD-FMK,
N-AM-G-F6V-AD-PMK,
NOTA-G-F6V-AD(OMe)-BMK,
NOTA-G-F6V-AD(OMe)-FM ,
NOTA-G-F6V-AD(OMe)-PMK,
NOTA-G-F6V-AD-BMK,
NOTA-G-F6V-AD-FMK,
NOTA-G-F6V-AD-PMK,
ORGn-G-F6V-AD(OMe)-BMK,
ORGn-G-F6V-AD(OMe)-FMK,
ORGn-G-F6V-AD(OMe)-PMK,
ORGn-G-F6V-AD-BMK,
ORGn-G-F6V-AD-FMK,
ORGn-G-F6V-AD-PMK,
TFA-G-F6V-AD(OMe)-BMK,
TFA-G-F6V-AD(OMe)-FMK,
TFA-G-F6V-AD(OMe)-PMK,
TFA-G-F6V-AD-BM ,
TFA-G-F6V-AD-FMK,
TFA-G-F6V-AD-PMK,
TFA-GVAD(OMe)-BMK,
TFA-GVAD(OMe)-FMK,
TFA-GVAD(OMe)-PMK,
TFA-GVAD-BMK,
TFA-GVAD-FMK,
TFA-GVAD-PMK,
TFMCBz-G-F6V-AD(OMe)-BMK,
TFMCBz-G-F6V-AD(OMe)-FMK,
TFMCBz-G-F6V-AD(OMe)-PMK,
TFMCBz-G-F6V-AD-BMK,
TFMCBz-G-F6V-AD-FMK,
TFMCBz-G-F6V-AD-PMK, TFMCBz-GVAD(OMe)-BMK, TFMCBz-GVAD(OMe)-FMK,
TFMCBz-GVAD(OMe)-PMK,
TFMCBz-GVAD-BMK,
TFMCBz-GVAD-FMK,
TFMCBz-GVAD-PMK,
Z-G-F6V-AD(OMe)-BMK,
Z-G-F6V-AD(OMe)-FMK,
Z-G-F6V-AD(OMe)-PMK,
Z-G-F6V-AD-BMK,
Z-G-F6V-AD-FMK,
Z-G-F6V-AD-PMK,
BODIPY-FL-D(OMe)E(OMe)VD(OMe)-FMK, BODIPY-FL-IE(OMe)TD(OMe)-FMK, BODIPY-FL-LE(OMe)HD(O e)-FMK, BODIPY-FL-LE(OMe)TD(OMe)-FMK, BODIPY-FL-VAD(OMe)-FMK,
BODIPY-FL-W(NMe)E(OMe)HD(OMe)-FMK, BODIPY-FL-WE(OMe)HD(OMe)-FMK, BODIPY-FL-YVAD(OMe)-FMK,
BODIPY-FL-VD(OMe)VAD(OMe)-FMK, BODIPY-FL-F6V-AD(OMe)-FMK
BODIPY-FL-D(OMe)E(OMe)VD(OMe)-PMK, BODIPY-FL-IE(OMe)TD(OMe)-PMK, BODIPY-FL-LE(OMe)HD(OMe)-PMK, BODIPY-FL-LE(OMe)TD(OMe)-PMK, BODIPY-FL-VAD(OMe)-PMK,
BODIPY-FL-W(NMe)E(OMe)HD(OMe)-PM , BODIPY-FL-WE(OMe)HD(OMe)-PMK, BODIPY-FL-YVAD(OMe)-PMK,
BODIPY-FL-VD(OMe)VAD(OMe)-PMK, BODIPY-FL-F6V-AD(OMe)-PMK BODIPY-FL-D(OMe)E(OMe)VD(OMe)-BMK, BODIPY-FL-IE(OMe)TD(OMe)-BMK,
BODIPY-FL-LE(OMe)HD(OMe)-BM ,
BODIPY-FL-LE(OMe)TD(OMe)-BMK,
BODIPY-FL-VAD(OMe)-BMK,
BODIPY-FL-W(NMe)E(OMe)HD(OMe)-BMK, BODIPY-FL-WE(OMe)HD(OMe)-BMK,
BODIPY-FL-YVAD(OMe)-BMK,
BODIPY-FL-VD(OMe)VAD(OMe)-BMK, BODIPY-FL-F6V-AD(OMe)-BMK
BODIPY-FL-D(OMe)E(OMe)VD(OMe)-OPH, BODIPY-FL-IE(OMe)TD(OMe)-OPH,
BODIPY-FL-LE(OMe)HD(OMe)-OPH,
BODIPY-FL-LE(OMe)TD(OMe)-OPH,
BODIPY-FL-VAD(OMe)-OPH,
BODIPY-FL-W(NMe)E(OMe)HD(OMe)-OPH, BODIPY-FL-WE(OMe)HD(OMe)-OPH,
BODIPY-FL-YVAD(OMe)-OPH,
BODIPY-FL-VD(OMe)VAD(OMe)-OPH, BODIPY-FL-F6V-AD(OMe)-OPH
BODIPY-TMR-D(OMe)E(OMe)VD(OMe)-FMK, BODIPY-TMR-IE(OMe)TD(OMe)-FMK, BODIPY-TMR-LE(OMe)HD(OMe)-FMK, BODIPY-TMR-LE(OMe)TD(OMe)-FM , BODIPY-TMR-VAD(OMe)-FMK,
BODIPY-TMR-W(NMe)E(OMe)HD(OMe)-FMK, BODIPY-TMR-WE(OMe)HD(OMe)-FMK, BODIPY-TR-D(OMe)E(OMe)VD(OMe)-FMK, BODIPY-TR-IE(OMe)TD(OMe)-FMK,
BODIPY-TR-LE(OMe)HD(OMe)-FMK,
BODIPY-TR-LE(OMe)TD(OMe)-FMK,
BODIPY-TR-VAD(OMe)-FMK, BODIPY-TR-W(NMe)E(OMe)HD(OMe)-FMK,
BODIPY-TR-WE(OMe)HD(OMe)-FM ,
TFA-VAD(OMe)-FMK,
TFA-VAD(OMe)-PM ,
TFA-VAD(OMe)-BMK,
TFA-VAD(OMe)-OPH,
TFA-F6V-AD(OMe)-FMK,
TFA-F6V-AD(OMe)-PMK,
TFA-F6V-AD(OMe)-OPH,
TFA-F6V-AD(OMe)-BMK,
TFA-WE(OMe)HD(OMe)-FMK,
TFA-WE(OMe)HD(OMe)-BMK,
TFA-WE(OMe)HD(OMe)-PMK,
TFA-WE(OMe)HD(OMe)-OPH,
TFA-YVAD(OMe)-FMK,
TFA-YVAD(OMe)-BMK,
TFA-YVAD(OMe)-PMK,
TFA-YVAD(OMe)-OPH,
TFA-GWE(OMe)HD(OMe)-FMK,
TFA-GWE(OMe)HD(OMe)-BMK,
TFA-GWE(OMe)HD(OMe)-PMK,
TFA-GWE(OMe)HD(OMe)-OPH,
TFA-GYVAD(OMe)-FMK,
TFA-GYVAD(OMe)-BM ,
TFA-GYVAD(OMe)-PMK,
TFA-GYVAD(OMe)-OPH
TFMCBZ-VAD(OMe)-FMK,
TFMCBZ-VAD(OMe)-PMK,
TFMCBZ-VAD(OMe)-BM ,
TFMCBZ-VAD(OMe)-OPH,
TFMCBZ-F6V-AD(OMe)-FMK,
TFMCBZ-F6V-AD(OMe)-PMK, TFMCBZ-F6V-AD(OMe)-OPH, TFMCBZ-F6V-AD(OMe)-BMK, TFMCBZ-WE(OMe)HD(OMe)-FMK, TFMCBZ-WE(OMe)HD(OMe)-BMK, TFMCBZ-WE(OMe)HD(OMe)-PMK, TFMCBZ-WE(OMe)HD(OMe)-OPH, TFMCBZ-YVAD(OMe)-FMK,
TFMCBZ-YVAD(OMe)-BM ,
TFMCBZ-YVAD(OMe)-PMK,
TFMCBZ-YVAD(OMe)-OPH,
TFMCBZ-GWE(OMe)HD(OMe)-FMK, TFMCBZ-GWE(OMe)HD(OMe)-BMK, TFMCBZ-GWE(OMe)HD(OMe)-PMK, TFMCBZ-GWE(OMe)HD(OMe)-OPH, TFMCBZ-GYVAD(OMe)-FMK, TFMCBZ-GYVAD(OMe)-BMK, TFMCBZ-GYVAD(OMe)-PM , TFMCBZ-GYVAD(OMe)-OPH
18F-VAD(OMe)-FMK,
18F-VAD(OMe)-PMK,
I 8F-VAD(OMe)-BMK,
18F-VAD(OMe)-OPH,
18F-F6V-AD(OMe)-FMK,
18F-F6V-AD(OMe)-PMK,
18F-F6V-AD(OMe)-OPH,
18F-F6V- AD(OMe)-BMK,
18F-WE(OMe)HD(OMe)-FMK,
18F-WE(OMe)HD(OMe)-BMK, 18F-WE(OMe)HD(OMe)-PMK, 18F-WE(OMe)HD(OMe)-OPH,
18F-YVAD(OMe)-FMK,
18F- YV AD(OMe)-BM , F- YV AD(OMe)-PMK,
18F-YVAD(OMe)-OPH,
18F-GWE(OMe)HD(OMe)-FMK,
18F-GWE(OMe)HD(OMe)-BMK,
18F-GWE(OMe)HD(OMe)-PMK,
18F-GWE(OMe)HD(OMe)-OPH,
18F-G YVAD(OMe)-FMK,
18F-GYVAD(OMe)-BMK,
18F-G YY AD(OMe)-PMK,
18F-GYVAD(OMe)-OPH,
BODIPY-W(NMe)E(OMe)HD(OMe)-BMK, BODIPY-W(NMe)E(OMe)HD(OMe)-FMK, BODIPY-W(NMe)E(OMe)HD(OMe)-PMK, ORGn-W(NMe)E(OMe)HD(OMe)-BMK, ORGn-W(NMe)E(OMe)HD(OMe)-FMK, ORGn-W(NMe)E(OMe)HD(OMe)-PMK, 780-W(N-TFM)E(OMe)HD(OMe)-BMK, 780-W(N-TFM)E(OMe)HD(OMe)-FMK, 780-W(N-TFM)E(OMe)HD(OMe)-PMK, ABzC-W(N-TFM)E(OMe)HD(OMe)-BMK, ABzC-W(N-TFM)E(OMe)HD(OMe)-FMK, ABzC-W(N-TFM)E(OMe)HD(OMe)-PMK, BODIPY-W(N-TFM)E(OMe)HD(OMe)-BMK, BODIPY-W(N-TFM)E(OMe)HD(OMe)-FMK, BODIPY-W(N-TFM)E(OMe)HD(OMe)-PMK, FAM-W(N-TFM)E(OMe)HD(OMe)-FMK, FAM-W(N-TFM)E(OMe)HD(OMe)-PMK, N-AE-W(N-TFM)E(OMe)HD(OMe)-BMK, N-AE-W(N-TFM)E(OMe)HD(OMe)-FMK, N-AE-W(N-TFM)E(OMe)HD(OMe)-PMK, N-AM-W(N-TFM)E(OMe)HD(OMe)-BMK, N-AM-W(N-TFM)E(OMe)HD(OMe)-FMK, N- AM- W(N -TFM)E(OMe)HD(OMe)-PMK, ORGn-W(N-TFM)E(OMe)HD(OMe)-BM , ORGn-W(N-TFM)E(OMe)HD(OMe)-FMK, ORGn-W(N-TFM)E(OMe)HD(OMe)-PM , BODIPY-W(N-Ac)E(OMe)HD(OMe)-BMK, BODIPY-W(N-Ac)E(OMe)HD(OMe)-FMK, BODlPY-W(N-Ac)E(OMe)HD(OMe)-PMK, ORGn-W(N-Ac)E(OMe)HD(OMe)-BMK, ORGn-W(N-Ac)E(OMe)HD(OMe)-FMK, ORGn-W(N-Ac)E(OMe)HD(OMe)-PMK, 780-W(N-TFA)E(OMe)HD(OMe)-BMK, 780-W(N-TFA)E(OMe)HD(OMe)-FMK, 780-W(N-TFA)E(OMe)HD(OMe)-PMK, BODIPY-W(N-TFA)E(OMe)HD(OMe)-BMK, BODIPY-W(N-TFA)E(OMe)HD(OMe)-FMK, BODIPY-W(N-TFA)E(OMe)HD(OMe)-PMK, F AM- W(N -TFA)E(OMe)HD(OMe)-BMK, FAM-W(N-TFA)E(OMe)HD(OMe)-FMK, FAM-W(N-TFA)E(OMe)HD(OMe)-PMK, ORGn-W(N-TFA)E(OMe)HD(OMe)-BMK, ORGn-W(N-TFA)E(OMe)HD(OMe)-FMK, ORGn-W(N-TFA)E(OMe)HD(OMe)-PMK, 780-5-F-W(NMe)E(OMe)HD(OMe)-BMK, 780-5-F-W(NMe)E(OMe)HD(OMe)-FMK, 780-5-F-W(NMe)E(OMe)HD(OMe)-PMK,
ABzC-5-F-W(NMe)E(OMe)HD(OMe)-BMK, ABzC-5-F-W(NMe)E(OMe)HD(OMe)-FMK, ABzC-5-F-W(NMe)E(OMe)HD(OMe)-PMK, ABzC-5-F-W(N-TFM)E(OMe)HD(OMe)-BM , ABzC-5-F-W(N-TFM)E(OMe)HD(OMe)-FMK, ABzC-5-F-W(N-TFM)E(OMe)HD(OMe)-PMK, BODIPY-5-F-W(NMe)E(OMe)HD(OMe)-BMK, BODIPY-5-F-W(NMe)E(OMe)HD(OMe)-FMK, BODIPY-5-F-W(NMe)E(OMe)HD(OMe)-PMK, FAM-5-F-W(NMe)E(OMe)HD(OMe)-BMK, FAM-5-F-W(NMe)E(OMe)HD(OMe)-FMK, FAM-5-F-W(NMe)E(OMe)HD(OMe)-PMK, N-AE-5-F-W(NMe)E(OMe)HD(OMe)-BMK, N-AE-5-F-W(NMe)E(OMe)HD(OMe)-FMK, N-AE-5-F-W(NMe)E(OMe)HD(OMe)-PMK, N-AE-5-F-W(N-TFM)E(OMe)HD(OMe)-BMK, N-AE-5-F-W(N-TFM)E(OMe)HD(OMe)-FMK, N-AE-5-F-W(N-TFM)E(OMe)HD(OMe)-PMK, N-AM-5-F-W(NMe)E(OMe)HD(OMe)-BMK, N-AM-5-F-W(NMe)E(OMe)HD(OMe)-FMK, N-AM-5-F-W(NMe)E(OMe)HD(OMe)-PMK, N-AM-5-F-W(N-TFM)E(OMe)HD(OMe)-BMK, N-AM-5-F-W(N-TFM)E(OMe)HD(OMe)-FMK, N-AM-5-F-W(N-TFM)E(OMe)HD(OMe)-PMK, ORGn-5-F-W(NMe)E(OMe)HD(OMe)-BMK, ORGn-5-F-W(NMe)E(OMe)HD(OMe)-FMK, ORGn-5-F-W(NMe)E(OMe)HD(OMe)-PMK, 780-2-CF3W(NMe)E(OMe)HD(OMe)-BMK, 780-2-CF3W(NMe)E(OMe)HD(OMe)-FMK, 780-2-CF3W(NMe)E(OMe)HD(OMe)-PMK, ABzC-2-CF3W(NMe)E(OMe)HD(OMe)-BMK, ABzC-2-CF3W(NMe)E(OMe)HD(OMe)-FMK, ABzC-2-CF3W(NMe)E(OMe)HD(OMe)-PMK, ABzC-2-CF3W(N-TFM)E(OMe)HD(OMe)-BMK, ABzC-2-CF3W(N-TFM)E(OMe)HD(OMe)-FMK, ABzC-2-CF3W(N-TFM)E(OMe)HD(OMe)-PMK, BODIPY-2-CF3W(NMe)E(OMe)HD(OMe)-BMK, BODIPY-2-CF3W(NMe)E(OMe)HD(OMe)-FMK, BODIPY-2-CF3W(NMe)E(OMe)HD(OMe)-PMK, FAM-2-CF3W(NMe)E(OMe)HD(OMe)-BMK, FAM-2-CF3W(NMe)E(OMe)HD(O e)-FMK, FAM-2-CF3W(NMe)E(OMe)HD(OMe)-PMK, N-AE-2-CF3W(N-TFM)E(OMe)HD(OMe)-BMK, N-AE-2-CF3W(N-TFM)E(OMe)HD(OMe)-FMK, N-AE-2-CF3W(N-TFM)E(OMe)HD(OMe)-PMK, N-AM-2-CF3W(N-TFM)E(OMe)HD(OMe)-BMK, N-AM-2-CF3W(N-TFM)E(OMe)HD(OMe)-FMK, N-AM-2-CF3W(N-TFM)E(OMe)HD(OMe)-PMK, ORGn-2-CF3W(NMe)E(OMe)HD(OMe)-BMK, ORGn-2-CF3W(NMe)E(OMe)HD(OMe)-FMK, ORGn-2-CF3W(NMe)E(OMe)HD(OMe)-PMK, 780-6-CF3W(NMe)E(OMe)HD(OMe)-BMK, 780-6-CF3W(NMe)E(OMe)HD(OMe)-FMK, 780-6-CF3W(NMe)E(OMe)HD(OMe)-PM ,
ABzC-6-CF3W(NMe)E(OMe)HD(OMe)-BMK, ABzC-6-CF3W(NMe)E(OMe)HD(OMe)-FMK, ABzC-6-CF3W(NMe)E(OMe)HD(OMe)-PM , ABzC-6-CF3W(N-TFM)E(OMe)HD(OMe)-BMK, ABzC-6-CF3W(N-TFM)E(OMe)HD(OMe)-FMK, ABzC-6-CF3W(N-TFM)E(OMe)HD(OMe)-PMK, BODIPY-6-CF3W(NMe)E(OMe)HD(OMe)-BMK, BODIPY-6-CF3W(NMe)E(OMe)HD(OMe)-FMK, BODIPY-6-CF3W(NMe)E(OMe)HD(OMe)-PMK, FAM-6-CF3W(NMe)E(OMe)HD(OMe)-BMK, FAM-6-CF3W(NMe)E(OMe)HD(OMe)-FMK, FAM-6-CF3W(NMe)E(OMe)HD(OMe)-PM , N-AE-6-CF3W(N-TFM)E(OMe)HD(OMe)-BMK, N-AE-6-CF3W(N-TFM)E(OMe)HD(OMe)-FMK, N-AE-6-CF3W(N-TFM)E(OMe)HD(OMe)-PMK, N-AM-6-CF3W(N-TFM)E(OMe)HD(OMe)-BMK, N-AM-6-CF3W(N-TFM)E(OMe)HD(OMe)-FMK, N-AM-6-CF3W(N-TFM)E(OMe)HD(OMe)-PMK,
ORGn-6-CF3W(NMe)E(OMe)HD(OMe)-BMK,
ORGn-6-CF3W(NMe)E(OMe)HD(OMe)-FMK, and
ORGn-6-CF3W(NMe)E(OMe)HD(OMe)-PMK.
The invention is illustrated by the following non-limiting Examples. The examples below are specific to caspase inhibitors; however, they generally apply to the Cysteine cathepsin inhibitors described herein as well.
EXAMPLES
Example 1.
Synthesis of Caspase Inhibitors (General Structure)
According to at least one embodiment, the caspase inhibitors can be synthesized using liquid phase peptide synthesis (Bodanszky, PRINCIPLES OF PEPTIDE SYNTHESIS (1993) or solid phase peptide synthesis (Merrifield, J Amer Chem Soc 85(14):2149-54 (1963); Amblard et al., Mol. Biotechnol., 33(3):239-54 (2006)). An example of a suitable liquid phase peptide synthetic pathway is shown below, and generally involves building oligo peptides from the N-terminus of an amino acid by providing a first amino acid (1); protecting or blocking the N terminus of the amino acid using a protecting or blocking group (e.g., BOC or FMOC); coupling the first amino acid with a C-terminal ester of a second amino acid (2) by reacting the amino acids in the presence of a coupling agent (e.g., dicyclohexyl carbodiimide (DCC), diisopropyl carbodiimide (DIC), usually in the presence of N-hydroxysuccinimide or 1 -hydroxybenzotriazole) to form a dipeptide (3); and deprotecting the dipeptide without removing any other protecting groups to yield the free dipeptide acid (4). Dipeptide (4) can be coupled to the suitably derivatized L- aspartic acid β-methyl ester to yield a desired caspase inhibitor or it can be coupled with a suitably protected amino acid to yield a fully protected tripeptide (5). If desired, by sequential deprotection of the C-terminus of 5 and analogous coupling to another suitably protected amino acid, a fully protected tetrapeptide may be constructed. Synthesized caspase inhibitors disclosed herein may be in the form of a waxy material or lyophilized powder.
Figure imgf000059_0001
Figure imgf000059_0002
The caspase inhibitor may be prepared by finishing the peptide chain with an aspartic acid portion and adding a fluoromethyl ketone (FMK), phenoxymethyl ketone (PMK), an OPH (2,6-difluorophenoxy ketone or 2,6-difluorophenoxymethyl ketone) group, or an acyloxymethyl ketone (AOMK) to the end of the peptide chain as a leaving group that is part of the reactive group and is positioned at the C-terminus of the recognition sequence of the caspase inhibitor. Alternatively, using a different protection strategy, FMOC-L-aspartic acid β-methyl ester may be made. From these molecules, FMK/PMK/OPH/AOMK can be attached to the a-carboxylic acid via a methylene group, introduced using diazomethane chemistry.
Example 2.
Characterization of Caspase Inhibitors: TFA-VAD(OMe)-FMK
Sequence: TFA-Val-Ala-Asp(OMe)-FMK
Molecular Weight: 429.4 amu
Solubility: 1 mg/mL in 10% Acetonitrile in H20
Appearance: White Lyophilized Powder
Mass Spec: M+=430.1 1
Example 3 TFA-VAD(OMe)-FMK is more potent than Z-VAD(OMe)-FMK and Q- VD(OMe)-OPH at inhibiting purified caspase-3.
Inhibitors and substrate (Ac-VAD-AMC final assay concentration = 50 μΜ) were mixed in assay buffer (50 niM HEPES pH 7.2, 50 mM NaCl, 0.1% CHAPS, 10 mM EDTA, 5% glycerol, 10 mM DTT) in 96-well plates. Recombinant human active caspase-3 (final assay concentration = 0.5 U/reaction) was added to each sample for a total reaction volume of 100 μΐ. Immediately after addition of caspase-3, plates were read at 37 °C with an excitation of 405 nm, an emission of 505 nm and an emission cutoff of 495 nm every 30 seconds for 1 hour using a Molecular Devices SpectraMax M2e plate reader.
All experiments were performed in duplicate, in two different days and three independent experiments. Prior to the inhibition experiment, the substrate was titrated with a constant concentration of enzyme, giving us a Km of 0.49782 μΜ, this number is used later to obtain the kapp. The amount of product was converted into percent of inhibited enzyme using the control or no inhibitor as a 0% inhibited and substrate only as our 100% inhibited.
The raw data were analyzed using a one-step exponential association curve to get the rates at different concentrations. Each curve was analyzed independently and only the curves which plateaued were used for further analysis by the rates obtained from said curves. These rates were then transformed into the apparent second order rate constant by using the
concentration of substrate, the concentration of enzyme, the concentration of inhibitor, the Km and the k value from the exponential association curve. The results showed Z-VAD-FMK having an apparent rate constant of 0.98 xl 06 M"1, sec"1 with Q-VD-OPH being a better inhibitor with a second order rate constant 1.6 xlO6 M"1, sec"1 and lastly TFA-VAD-FMK being the best inhibitor with a second order rate constant 7.5 xlO6 M"1, sec"1. (Figure 1 and 2).
Example 4 TFA-VAD(OMe)-FMK is more potent at inhibiting staurosporine-induced caspase activity compared to Z-VAD(OMe)-FMK and Q-VD(OMe)-FMK.
Inhibitors (10 μΜ) were added to 1 x 106 Jurkat cells (human T lymphocyte cell line) for 15 minutes in a total volume of 1 ml cell culture medium (RPMI + 10% FBS) at 37°C. 1 μΜ Staurosporine (protein kinase inhibitor) was added and cells were incubated for 3.5 hours at 37°C to induce apoptosis. After 3.5 hours, CAS-MAP active caspase labeling reagent (FAM- VAD(OMe)-FMK, 0.75 μΜ) was added and cells were incubated for 20 minutes at 37°C to label active caspases. Cells were collected, washed with PBS, and resuspended in 1 ml PBS for flow cytometry analysis using a Life Technologies Attune NxT acoustic focusing cytometer (488 nm excitation laser, 530 nm/30 nm band pass emission filter). An increase in FAM-VAD- FMK fluorescence intensity correlates with caspase activity. (Figure 4) Example 5 TFA-VAD(OMe)-FM is a more potent than Z-VAD(OMe)-FMK at inhibiting apoptosis.
Jurkat cells (1 x 106 cells, 1 ml total volume in RPMI + 10% FBS) were incubated at 37°C with the indicated concentrations of TFA-VAD(OMe)-FMK or Z-VAD(OMe)-FMK for 15 minutes prior to apoptosis induction with 1 μΜ Staurosponne (protein kinase inhibitor) for 4 hours at 37°C, 5 μΜ Camptothecin (topoisomerase I inhibitor) for 4 hours at 37°C or 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours at 37°C. Cells were washed with annexin V binding buffer (140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4) and resuspended in 100 μΐ annexin V binding buffer. 5 μΐ Annexin V - Alexa Fluor 488 (Thermo Scientific) was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes. 1 ml of annexin V binding buffer was added to each sample followed by 1 μΐ SYTOX AADvanced (Thermo Scientific). Cells were incubated in the dark, at room temperature for 5 minutes prior to flow cytometry analysis using a Life Technologies Attune NxT acoustic focusing cytometer (488 nm excitation laser, 530 nm/30 nm band pass emission filter for annexin V- Alexa Fluor 488 and 488 nm excitation laser, 695 nm/40 nm band pass emission filter for SYTOX
AADvanced). % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. Data were normalized to no inhibitor samples (unstimulated = 0%, stimulated = 100%) and percent inhibition was calculated. (Figure 5)
Example 6 TFA-VAD(OMe)-FMK inhibits staurosporine-induced apoptosis after 24 hours in cell culture.
Jurkat cells (1 x 106 cells, 1 ml total volume in RPMI + 10% FBS) were incubated with 10 μΜ TFA-VAD(OMe)-FMK or 10 μΜ Z-VAD(OMe)-FMK for 24 hours at 37°C. After 24 hours, apoptosis was induced with 1 μΜ staurosporine for 4 hours at 37°C. Cells were washed with annexin V binding buffer (140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4) and resuspended in 100 μΐ annexin V binding buffer. 5 μΐ Annexin V - Alexa Fluor 488 (Thermo Scientific) was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes. 1 ml of annexin V binding buffer was added to each sample followed by 1 μΐ SYTOX AADvanced (Thermo Scientific). Cells were incubated in the dark, at room
temperature for 5 minutes prior to flow cytometry analysis using a Life Technologies Attune
NxT acoustic focusing cytometer (488 nm excitation laser, 530 nm 30 nm band pass emission filter for annexin V- Alexa Fluor 488 and 488 nm excitation laser, 695 nm/40 nm band pass emission filter for SYTOX AADvanced). % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. (Figure 6)
Example 7 TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit caspase-3/7 activity in Hep G2 cells.
Hep G2 cells (human hepatocyte carcinoma cell line) were seeded in 96 well plates at 1 x 104 cells/well in DMEM + 10% FBS and incubated for 24 hours at 37°C. Inhibitors were added to the indicated concentrations and cells were incubated for 15 minutes at 37°C. Caspase activity was induced by treating cells with 2 μ§ ηύ anti-TRAIL R2 agonist antibody for 24 hours at 37°C in a total volume of 60 μΐ in DMEM + 10% FBS. After 24 hours, 60 μΐ of a 2X solution containing a caspase-3/7 specific fluorescent substrate (Ac-Asp-Phe(F5)-Val-Asp-ACC, 2X = 200 μΜ) was added to each sample in a duel function cell lysis/caspase activity buffer (2X = 20% sucrose, 100 mM HEPES pH 7.4, 20 mM NaCl, 10 mM MgC12, 0.8 mM EGTA, 0.2% CHAPS, 1% TWEEN 20). After 2 hours of substrate incubation, fluorescence was determined with an excitation wavelength of 355 nm and an emission wavelength of 460 nm with a cutoff of 455 nm using a Molecular Devices SpectraMax M2e plate reader. Relative Fluorescent Units were normalized to no inhibitor samples (no anti-TRAIL R2 antibody = 0%, + anti-TRAIL R2 antibody = 100%) and percent inhibition was calculated. (Figure 7)
Example 8 TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH and TFA-VD(OMe)-TPH inhibit staurosporine-induced apoptosis in Jurkat cells.
Jurkat cells (1 x 106 cells, 1 ml total volume in RPMI + 10% FBS) were incubated with 5 μΜ of the indicated caspase inhibitor for 15 minutes prior to stimulation with 1 μΜ
staurosporine for 4 hours at 37°C. Cells were washed with annexin V binding buffer (140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4) and resuspended in 100 μΐ annexin V binding buffer. 5 μΐ Annexin V - Alexa Fluor 488 (Thermo Scientific) was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes. 1 ml of annexin V binding buffer was added to each sample followed by 1 μΐ SYTOX AADvanced (Thermo Scientific). Cells were incubated in the dark, at room temperature for 5 minutes prior to flow cytometry analysis using a Life Technologies Attune NxT acoustic focusing cytometer (488 nm excitation laser, 530 nm/30 nm band pass emission filter for annexin V- Alexa Fluor 488 and 488 nm excitation laser, 695 nm/40 nm band pass emission filter for SYTOX AADvanced). %
Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. Data were normalized to no inhibitor samples (unstimulated = 0%, stimulated = 100%) and percent inhibition was calculated. TFA-EVD-TPH and TFA-6E8D-TPH inhibited apoptosis to a lesser extent than TFA-VAD-FMK, TFA-VAD-TPH and TFA-VD-TPH in staurosporine-induced Jurkat cells. (Figure 8)
Example 9 TFA-VAD(OMe)-FMK, TFA-VAD(OMe)-TPH, TFA-VD(OMe)-TPH, TFA- EVD-TPH and TFA-6E8D-TPH inhibit anti-TRAIL R2 antibody-induced apoptosis in Jurkat cells.
Jurkat Cells (1 x 106 cells, 1 ml total volume in RPMI + 10% FBS) were incubated with the indicated concentrations of caspase inhibitor for 15 minutes prior to stimulation with 100 ng/ml anti-TRAIL R2 agonist antibody for 24 hours at 37°C. Cells were washed with annexin V binding buffer (140 mM NaCl, 2.5 mM CaC12, 10 mM HEPES pH 7.4) and resuspended in 100 μΐ annexin V binding buffer. 5 μΐ Annexin V - Alexa Fluor 488 (Thermo Scientific) was added to each sample and cells were incubated in the dark, at room temperature for 15 minutes. 1 ml of annexin V binding buffer was added to each sample followed by 1 μΐ SYTOX AADvanced (Thermo Scientific). Cells were incubated in the dark, at room temperature for 5 minutes prior to flow cytometry analysis using a Life Technologies Attune NxT acoustic focusing cytometer (488 nm excitation laser, 530 nm/30 nm band pass emission filter for annexin V- Alexa Fluor 488 and 488 nm excitation laser, 695 nm/40 nm band pass emission filter for SYTOX
AADvanced). % Apoptosis was calculated by adding the percentage of cells in the Annexin V positive/SYTOX negative and Annexin V positive/SYTOX positive populations. Data were normalized to no inhibitor samples (unstimulated = 0%, stimulated = 100%) and percent inhibition was calculated. (Figure 9) Example 10 TFA-FK-TPH and TFA-FR-TPH inhibit cathepsins in intact RAW 264.7 cells.
RAW 264.7 cells (mouse macrophage cell line) were plated in 6 well plates at 8 x 10 cells/well in DMEM + 10% FBS and allowed to grow overnight at 37°C. The next day, cells were treated with the indicated concentrations of TFA-FK-TPH, TFA-FR-TPH or E64d (a general cysteine cathepsin and calpain inhibitor) for 1 hour at 37°C followed by the addition of 1 μΜ BMV109 (a Cy5 labeled activity based probe that binds cathepsin B, L, S and X) for 2 hours at 37°C to label active cathepsins. Cells were washed with cold PBS, resuspended in 50 μΐ hypotonic lysis buffer (50 mM PIPES pH 7.4, 10 mM KC1, 5 mM MgC12, 2 mM EDTA, 1% Nonidet P-40, 4 mM DTT) and incubated on ice for 10 minutes. Lysates were spun at 17,000 x g for 10 minutes at 4°C and supernatants were collected and assayed for protein concentration using the Pierce 660 nm Protein Assay. 50 μg of cell lysate was separated by SDS-PAGE on 15% Mini-PROTEAN TGX precast gels (Bio-Rad). Gels were scanned using a GE Typhoon FLA 9500 (Cy5). TFA-FK-TPH was found to be a much more potent cathepsin inhibitor in intact RAW 264.7 cells than TFA-FR-TPH.
Example 11 Preparation of Representative Compounds of the Invention
As illustrated below, the following representative compounds of the invention were prepared by standard SPPS; the acid moieties were transformed to the 1 -(2,3,5,6- tetrafluorophenoxy)acetyl group by solution chemistry. Final products were confirmed by mass spectrometry.
Figure imgf000064_0001
TFA-EVD-TPH; Mass Spec [M+H]+=621.1
Figure imgf000064_0002
TFA-6E8D-TPH; Mass Sp +=724.8
Figure imgf000065_0001
TFA-VAD(OMe)-TPH; Mass Spec [M+H]+=575.9
Figure imgf000065_0002
TF A- VD(OMe)-TPH ; Mass Spec [M+H]+=505.1
Figure imgf000065_0003
TFA-FK-TPH; Mass Spec [M+H]+=552.1
Figure imgf000065_0004
TFA-FR-TPH; Mass Spec [M+H]+=581.2
Figure imgf000066_0001
Example 12 Preparation of Representative Compounds of the Invention
Representative compounds of the invention can also be prepared as illustrated below.
XC02Bn 1 . CIC02CH2CHMe2) NM , THF
2. CH2N2, EtzO
Joc N C02H 3. HBr (aqueous) ^ Bqc HN ^
101 (Tetrahedron, 1997, 53, 5325)
Figure imgf000066_0002
[Bi∞rg. Med. Chem. Lett , 1997, 19, 199) Intermediate compound 110 can be used to prepare compounds having D-TPH at the carboxy terminus. Similar intermediate compounds can be prepared to provide compounds having the functionality X-J at the carboxy terminus, wherein X is an amino acid or an appropriately protected amino acid and J has any of the values defined herein, by selection of the starting amino acid 101.
Solid-phase peptide synthesis (SPPS) can be used to prepare peptide sequences that can be incorporated in to compounds of the invention. Coupling of the carboxy terminus of a peptide sequences 111 with an intermediated of formula 110 followed by optional deprotection and optional functionalization of the N-terminus can provide compounds of the invention as illustrated below. 1. Solid-phase peptide synthesis (SPPS)
2. Cleave peptide from resin to C-
Figure imgf000067_0001
terminal C02H (leave amino acid side
chains protected)
AA1-AAn-C02H
111
1. PyBOP, DIEA, D F
2. Deprotection
Figure imgf000067_0002
N-terminal functionality
Figure imgf000067_0003
All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference (including United States Provisional Application Number 62/222586, International Patent Application Publication Number WO2015/175381 Al, United States Patent Number 8,673,904, United States Patent Application Publication Number 2009/0203629, Berger, A. B., et al., 2006, Mol. Cell 23, 509-21 ; Van der Linden, W., et al., 2016, ACS Infectious Diseases 2, 173-17; Albeck, A. and Estreicher, G., Tetrahedron, 1997, 53, 5325; and Ueno, H., et al., Bioorg. Med. Chem. Lett., 1997, 19, 199). The invention has been described with reference to various specific and preferred embodiments and
techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims

CLAIMS What is claimed is:
1. A compound of formula (If):
CF3-C(=0)-X-THP (If)
wherein X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V- D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E-8D(OMe), V-A-D(OMe). V-D, V-D(OMe), F-K, F-R,VAD, EVD, D-3-V-D, L-E-H-D (SEQ ID NO:9), L-E-T-D (SEQ ID NO: 10), D-E-V-D (SEQ ID NO:3), D-E-P-D (SEQ ID NO:7), D-29-V-D, D-34-V-D, 26-34- V- D, 26-3-V-D, 26-E-V-D, 31-E-T-D, 31-E-23-D, 29-E-T-D, 6-E-8-D, D-E-l l-D, D-30-11-D, D- 30- V-D, P-L-A-D (SEQ ID NO:8), I-L-A-D (SEQ ID NO:l 1), I-L-38-D, I-F-P-D (SEQ ID NO: 12), D-3-V-D, D-34-V-D, 31-E-23-D, and P-L-A-D (SEQ ID NO:8), wherein the numbers 3, 6, 8, 11, 23, 26, 29, 30, 31, 34, and 38 represent the following structures:
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
2. The compound of claim 1 wherein X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E- 8D(OMe), V-A-D(OMe). V-D, V-D(OMe), F-K, F-R,VAD, EVD, and 6-E-8-D.
3. The compound of claim 1 wherein X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E- 8D(OMe), V-A-D(OMe). V-D, V-D(OMe), VAD, EVD, and 6-E-8-D.
4. The compound of claim 1 wherein X is a peptide selected from the group consisting of: F-K and F-R.
5. The compound of claim 1 which is selected from the group consisting of:
TFA-EVD-TPH;
TFA-6E8D-TPH;
TFA-VAD(OMe)-TPH;
TFA-VD(OMe)-TPH;
TFA-FK-TPH; and
TFA-FR-TPH.
6. A compound of formula (I):
UrX-J-U2 (I)
wherein:
Ui is absent or is a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms; and U2 is absent or is a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms; wherein at least one of U] and U2 is present;
X is a molecule that will recognize a cysteine protease; and J is a reactive group that binds to a cysteine protease.
7. The compound of claim 6 which is a compound of formula (la):
Ui-X-J (la).
8. The compound of claim 6 which is a compound of formula (lb):
X-J-U2 (lb).
9. The compound of claim 6 which is a compound of formula (Ic):
CF3-C(=0)-X-J (Ic).
10. The compound of any one of claims 6-9 wherein X is a molecule that will recognize a caspase or cysteine cathepsin.
1 1. The compound of any one of claims 6-10 wherein X is a peptide that contains 1-8 amino acids.
12. The compound of any one of claims 6-10 wherein X is a peptide that contains 2-5 amino acids.
13. The compound of any one of claims 6-9 wherein X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8- D(OMe), 6-E-8D(OMe), V-A-D(OMe). V-D, V-D(OMe), F-K, F-R,VAD, EVD, D-3-V-D, L-E- H-D (SEQ ID NO:9), L-E-T-D (SEQ ID NO: 10), D-E-V-D (SEQ ID NO:3), D-E-P-D (SEQ ID NO:7), D-29-V-D, D-34-V-D, 26-34-V-D, 26-3-V-D, 26-E-V-D, 31-E-T-D, 31-E-23-D, 29-E- T-D, 6-E-8-D, D-E-11-D, D-30-11-D, D-30-V-D, P-L-A-D (SEQ ID NO:8), I-L-A-D (SEQ ID NO:l l), I-L-38-D, I-F-P-D (SEQ ID NO: 12), D-3-V-D, D-34-V-D, 31-E-23-D, and P-L-A-D (SEQ ID NO:8), wherein the numbers 3, 6, 8, 11, 23, 26, 29, 30, 31 , 34, and 38 represent the following structures:
Figure imgf000072_0001
71
Figure imgf000073_0001
14. The compound of claim 13 wherein X is a peptide selected from the group consisting of: VD, VAD, EVD, D-3-V-D, L-E-H-D (SEQ ID NO:9), L-E-T-D (SEQ ID NO: 10), D-E-V-D (SEQ ID NO:3), D-E-P-D (SEQ ID NO:7), D-29-V-D, D-34-V-D, 26-34-V-D, 26-3-V-D, 26-E- V-D, 31-E-T-D, 31-E-23-D, 29-E-T-D, 6-E-8-D, D-E-l l-D, D-30-1 1 -D, D-30-V-D, P-L-A-D (SEQ ID NO:8), I-L-A-D (SEQ ID NO:l 1), I-L-38-D, I-F-P-D (SEQ ID NO: 12), D-3-V-D, D- 34-V-D, 31 -E-23-D, and P-L-A-D (SEQ ID NO:8).
15. The compound of claim 13 wherein X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E- 8D(OMe), V-A-D(OMe). V-D, V-D(OMe), F-K, F-R,VAD, EVD, and 6-E-8-D.
16. The compound of claim 13 wherein X is a peptide selected from the group consisting of: E(OMe)-V-D, E(OMe)-V-D(OMe), E-V-D(OMe), 6-E(OMe)-8-D, 6-E(OMe)-8-D(OMe), 6-E- 8D(OMe), V-A-D(OMe). V-D, V-D(OMe), VAD, EVD, and 6-E-8-D.
17. The compound of claim 13 wherein X is a peptide selected from the group consisting of: F-K and F-R.
18. The compound of any one of claims 6-17 wherein J is selected from the group consisting of AMOK, BMK, FMK, OPH, PMK, and TPH.
19. The compound of any one of claims 6-17 wherein J is selected from the group consisting of AMOK, OPH, PMK, and TPH.
20. The compound of any one of claims 6-17 wherein J is TPH.
21. The compound of claim 6 which is a compound of formula (Id):
(U)-X-J-(U) (Id)
wherein:
U is present on at least one end of the molecule and consists of a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms;
X is any molecule that will recognize a cysteine protease; and
J is any reactive group that binds to a caspase or cysteine cathepsin.
22. The compound of claim 21 , wherein U is a trifluoroacetyl (TFA) group that may be connected directly or indirectly (i.e. via linker).
23. The compound of claim 21 or 22 which is a compound of formula (Ie):
(U)-X-NH-CH(R)-CO-CH2-J(U) (Ie)
wherein:
U is a fluorinated group comprising 1-10 carbon atoms and one or more fluorine atoms
X is a peptide-based caspase recognition sequence comprising 1-8 amino acids;
R is -CH2C02CH3, -CH2C02H; and
J is any reactive group that binds to a caspase.
24. The compound of claim 23 wherein U is a trifluoroacetyl (TFA) group that may be connected directly or indirectly (i.e. via linker).
25. The compound of any one of claims 21-24 wherein X comprises at least one amino acid selected from alanine, aspartic acid, glutamic acid, histidine, glycine, arginine, lysine, methionine, proline, isoleucine, phenylalanine, leucine, threonine, tryptophan, valine, tyrosine, glutamine, serine, pyrrolysine, selenocysteine, norvaline, norleucine and synthetic analogs thereof.
26. The compound of any one of claims 21-24 wherein X comprises VAD(OMe),
VD(OMe), VAD, VD, E(OMe)VD(OMe), EVD, 6E8D, 6E(OMe)8D(OMe), FK, FR, GGR, WE(OMe)HD(OMe), IE(OMe)TD(OMe), D(OMe)E(OMe)VD(OMe), LE(OMe)HD(OMe), LE(OMe)TD(OMe), YVAD(OMe), VD(OMe)VAD(OMe) or any of the following: Asp-3,4 Difluorophenylalanine-Val-Asp, Asp-Pentafluorophenylalanine-Val-Asp, (2- Oxoacetamido)(Propanamido)-4-Oxo-Pentanoic Acid, (Oxiran-2-yl) Carbonyl-L-Leucyl-3-(p- Hydroxyphenyl) Ethylamide.
27. The compound of any one of claims 21-24 wherein X is VAD(OMe), VD(OMe), VAD, VD, E(OMe)VD(OMe), EVD, 6E8D, 6E(OMe)8D(OMe), FK, FR, GGR, WE(OMe)HD(OMe), IE(OMe)TD(OMe), D(OMe)E(OMe)VD(OMe), LE(OMe)HD(OMe), LE(OMe)TD(OMe), YVAD(OMe), VD(OMe)VAD(OMe) or any of the following: Asp-3,4 Difluorophenylalanine- Val-Asp, Asp-Pentafluorophenylalanine-Val-Asp, (2-Oxoacetamido)(Propanamido)-4-Oxo- Pentanoic Acid, (Oxiran-2-yl) Carbonyl-L-Leucyl-3-(p-Hydroxyphenyl) Ethylamide.
28. The compound of any one of claims 21-24 wherein J is any molecule that will react with active cysteine proteases, e.g.a halomethyl ketone (such as CMK, FMK), a substituted or unsubstituted phenoxymethyl ketone (PMK), an acyloxymethyl ketone (AOMK), or an epoxide.
29. A compound of claims 21 which is selected from
TFA-VAD(OMe)-FMK TFA-YVAD(OMe)-FMK TFA-WE(OMe)HD(OMe)-FMK
TFA-VAD(OMe)-PMK TFA-YVAD(OMe)-PMK TFA-WE(OMe)HD(OMe)-PMK TFA-VAD(OMe)-OPH TFA-YYAD(OMe)-OPH TFA-WE(OMe)HD(OMe)-OPH TFA-VAD(OMe)-TPH TFA-YVAD(OMe)-TPH TFA-WE(OMe)HD(OMe)-TPH TFA-VAD(OMe)-AOMK TFA-YVAD(OMe)-AOMK TFA- WE(OMe)HD(OMe)- AOMK TFA-IE(OMe)TD(OMe)-FMK TFA-D(OMe)E(OMe)VD(OMe)-FMK
TFA-IE(OMe)TD(OMe)-PMK TFA-D(OMe)E(OMe)VD(OMe)-PMK
TFA-IE(OMe)TD(OMe)-OPH TFA-D(OMe)E(OMe)VD(OMe)-OPH
TFA-IE(OMe)TD(OMe)-TPH TFA-D(OMe)E(OMe)VD(OMe)-TPH
TFA-IE(OMe)TD(OMe)-AOMK TFA-D(OMe)E(OMe)VD(OMe)-AOMK
TFA-LE(OMe)HD(OMe)-FMK TFA-LE(OMe)TD(OMe)-FMK TFA-EVD-FMK TFA-LE(OMe)HD(OMe)-PMK TFA-LE(OMe)TD(OMe)-PMK TFA-EVD-PMK TFA-LE(OMe)HD(OMe)-OPH TFA-LE(OMe)TD(OMe)-OPH TFA-EVD-OPH TFA-LE(OMe)HD(OMe)-TPH TFA-LE(OMe)TD(OMe)-TPH TFA-EVD-TPH TFA-LE(OMe)HD(OMe)-AOMK TFA-LE(OMe)TD(OMe)-AOMK TFA-EVD-AOMK TFA-VD(OMe)VAD(OMe)-FMK TFA-VD(OMe)-FMK TFA-E(OMe)VD(OME)- FMK
TFA-VD(OMe)VAD(OMe)-PMK TFA-VD(OMe)-PMK TFA-E(OMe)VD(OMe)- PMK
TFA-VD(OMe)VAD(OMe)-OPH TFA-VD(OMe)-OPH TFA-E(OMe)VD(OMe)- OPH
TFA-VD(OMe)VAD(OMe)-TPH TFA-VD(OMe)-TPH TFA-E(OMe)VD(OMe)-
TPH
TFA-VD(OMe)VAD(OMe)-AOMK TFA-VD(OMe)-AOMK TFA-E(OMe)VD(OMe)- AOMK TFA-VAD-FMK TFA-VD-FMK TFA-6E8D-FMK TFA-6E(OMe)8D(OMe)-
FMK
TFA-VAD-PMK TFA-VD-PMK TFA-6E8D-PMK TFA-6E(OMe)8D(OMe)-
PMK
TFA-VAD-OPH TFA-VD-OPH TFA-6E8D-OPH TFA-6E(OMe)8D(OMe)-
OPH
TFA-VAD-TPH TFA-VD-TPH TFA-6E8D-TPH TFA-6E(OMe)8D(OMe)-
TPH
TFA-VAD-AOMK TFA-VD-AOMK TFA-6E8D-AOMK TFA-6E(OME)8D(OMe)-
AOMK
TFA-GGR-FMK TFA-FK-FMK TFA-FR-FMK
TFA-GGR-PMK TFA-FK-PMK TFA-FR-PMK
TFA-GGR-OPH TFA-F -OPH TFA-FR-OPH
TFA-GGR-TPH TFA-FK-TPH TFA-FR-TPH
TFA-GGR-AOMK TFA-FK-AOMK TFA-FR-AOMK and the following compounds:
Figure imgf000077_0001
Figure imgf000078_0001
30. A pharmaceutical composition comprising a compound as described in any one of claims 1-29 and a pharmaceutically acceptable excipient, and optionally a therapeutic agent.
31. The composition of claim 30 wherein the excipient comprises sucrose, lactose, cellulose, gelatin, polyvinylpyrrolidone, trehalose, cyclodextrin, hyaluronic acid, polyethylene glycol or water.
32. The composition of claim 30 wherein the therapeutic agent is a cancer-targeted chemotherapeutic agent.
33. A method for inhibiting a cysteine protease in vitro or in vivo comprising contacting the cysteine protease with a compound as described in any one of claims 1-29.
34. A method for inhibiting a cysteine protease in vitro or in vivo comprising contacting the caspase with a compound as described in any one of claims 1-29.
35. The method of claim 33 wherein the compound inhibits the cysteine protease by forming an irreversible covalent bond to the active site of a cysteine protease.
36. A method for treating a disease or condition associated with an increase in cellular apoptosis and/or inflammation in a subject (e.g. animal or human) comprising administering to the subject a compound as described in any one of claims 1-29.
37. The method of claim 36 wherein the disease or condition is myocardial infarction, stroke, traumatic brain injury, spinal atrophy, auto-immune diseases (e.g. Alzheimer's), fulminant liver destruction, endotoxic shock, sepsis, septic shock, liver disease such as chronic hepatitis
(including virus-related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH"), pancreatitis, arthritis, viral infection, metabolic disease, cancer, implant or transplant rejection, neurodegenerative diseases (e.g. multiple sclerosis), pulmonary fibrosis, cardiac fibrosis, renal fibrosis, liver fibrosis and cirrhosis or ototoxicity.
38. A method for inhibiting apoptosis and/or inflammation (including diseases or conditions associated with apoptosis and/or inflammation) in a subject (e.g. animal or human) comprising administering to the subject a compound as described in any one of claims 1-29.
39. A method for inhibiting apoptosis and/or inflammation in a cell population by
administering in vitro a compound as described in any one of claims 1-29 to a biological sample to provide a resulting sample, and incubating the resulting sample under conditions sufficient to form caspase-inhibitor or cysteine cathepsin-inhibitor complexes.
40. The method of claim 39 wherein the biological sample comprises blood sample, tissue, a cell suspension, a cellular extract, or a tissue homogenate.
41. A method for preventing and/or treating a caspase-mediated or cysteine cathepsin- associated disease or condition in an subject (e.g. animal of human), comprising administering to the subject a compound as described in any one of claims 1-29.
42. A kit comprising:
1 ) a compound as described in any one of claims 1 -29; and
2) instructions for using the compound to inhibit a cysteine protease or to treat a cysteine protease-mediated disease or condition.
43. A kit comprising:
1) a compound as described in any one of claims 1-29; and
2) instructions for using the compound to inhibit a caspase or to treat a caspase- mediated disease or condition or a cysteine cathepsin-associated disease or condition.
44. A method of inhibiting caspase or cysteine cathepsin activity in a cell-free system, comprising adding a compound as described in any one of claims 1-29 to the purified caspases.
45. A compound as described in any one of claims 1-29 for the prophylactic or therapeutic treatment of a disease or condition associated with an increase in cellular apoptosis and/or inflammation.
46. The compound of claim 45 wherein the disease or condition is myocardial infarction, stroke, traumatic brain injury, spinal atrophy, auto-immune diseases (e.g. Alzheimer's), fulminant liver destruction, endotoxic shock, sepsis, septic shock, liver disease such as chronic hepatitis (including virus-related hepatitis, alcoholic steatohepatitis and non-alcoholic steatohepatitis or "NASH"), pancreatitis, arthritis, viral infection, metabolic disease, cancer, implant or transplant rejection, neurodegenerative diseases (e.g. multiple sclerosis), pulmonary fibrosis, cardiac fibrosis, renal fibrosis, liver fibrosis and cirrhosis or ototoxicity.
47. A compound as described in any one of claims 1-29 for the prophylactic or therapeutic treatment of inflammation.
48. A compound as described in any one of claims 1-29 for inhibiting apoptosis.
49. A method to treat cancer in a subject (e.g. animal or human) comprising administering to the subject a compound as described in any one of claims 1-29.
50. A compound as described in any one of claims 1-22 for the prophylactic or therapeutic treatment of cancer.
PCT/US2016/053539 2015-09-23 2016-09-23 Cysteine protease inhibitors WO2017053864A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562222586P 2015-09-23 2015-09-23
US62/222,586 2015-09-23
US201662344251P 2016-06-01 2016-06-01
US62/344,251 2016-06-01

Publications (1)

Publication Number Publication Date
WO2017053864A1 true WO2017053864A1 (en) 2017-03-30

Family

ID=57121532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/053539 WO2017053864A1 (en) 2015-09-23 2016-09-23 Cysteine protease inhibitors

Country Status (1)

Country Link
WO (1) WO2017053864A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110893171A (en) * 2019-12-30 2020-03-20 济源市万洋华康生物科技有限公司 Preparation method of composition for inhibiting wound cicatricial healing
WO2020181165A1 (en) * 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
EP3766873A4 (en) * 2018-03-13 2021-12-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing caspase inhibitor
CN114504637A (en) * 2020-09-04 2022-05-17 复旦大学附属中山医院 Application of GSDMD inhibitor in atherosclerosis
WO2022261473A1 (en) * 2021-06-11 2022-12-15 The Scripps Research Institute Protease inhibitors for the treatment of coronavirus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053752A2 (en) * 2003-11-26 2005-06-16 Ge Healthcare Limited Novel imaging agents comprising caspase-3 inhibitors
WO2016065174A1 (en) * 2014-10-22 2016-04-28 Seed Research And Development Llc Caspase probes for detection of apoptosis
WO2016090169A1 (en) * 2014-12-03 2016-06-09 Seed Research And Development Llc Intracellular caspase probes for detection of apoptosis and inflammation and kits containing such probes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053752A2 (en) * 2003-11-26 2005-06-16 Ge Healthcare Limited Novel imaging agents comprising caspase-3 inhibitors
WO2016065174A1 (en) * 2014-10-22 2016-04-28 Seed Research And Development Llc Caspase probes for detection of apoptosis
WO2016090169A1 (en) * 2014-12-03 2016-06-09 Seed Research And Development Llc Intracellular caspase probes for detection of apoptosis and inflammation and kits containing such probes

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
"Q-VD-OPH, a broad spectrum caspase inhibitor with anti-apoptotic properties", APOPTOSIS, 8 August 2003 (2003-08-08), pages 345 - 352
ALBECK, A.; ESTREICHER, G., TETRAHEDRON, vol. 53, 1997, pages 5325
AMBLARD ET AL., MOL. BIOTECHNOL., vol. 33, no. 3, 2006, pages 239 - 254
BERGER, A. B. ET AL., MOL. CELL, vol. 23, 2006, pages 509 - 521
BODANSZKY, PRINCIPLES OF PEPTIDE SYNTHESIS, 1993
BRUMATTI ET AL.: "The Caspase-8 Inhibitor Emricasan Combines With the SMAC Mimetic Birinapant to Induce Necroptosis and Treat Acute Myeloid Leukemia", SCI TRANS MED, vol. 8, 2016, pages 339RA69
CHENG ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 1992 - 1999
EKERT P G ET AL: "CASPASE INHIBITORS", CELL DEATH AND DIFFERENTIATION, NATURE PUBLISHING GROUP, GB, vol. 6, no. 11, 1 November 1999 (1999-11-01), pages 1081 - 1086, XP008011543, ISSN: 1350-9047, DOI: 10.1038/SJ.CDD.4400594 *
ENDRES ET AL., J. CEREBRAL BLOOD FLOW AND METABOLISM, vol. 18, 1998, pages 238 - 247
GARCIA-CALVO ET AL., J. BIOL. CHEM., vol. 273, no. 49, 1998, pages 32608 - 32613
GOLDE ET AL., SCIENCE, vol. 255, 1992, pages 728 - 730
HOOK ET AL., FRONTIERS IN NEUROLOGY, vol. 6, 2015, pages 178
IWATA ET AL., ARTHRITIS AND RHEUMATISM, vol. 40, 1997, pages 499 - 509
JOYCE ET AL., CANCER CELL, vol. 5, 2004, pages 443 - 453
LINTON STEVEN D ET AL: "Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 14, no. 10, 1 January 2004 (2004-01-01), pages 2685 - 2691, XP002510183, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2003.12.106 *
MACKENZIE S H ET AL: "The potential for caspases in drug discovery", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 13, no. 5, 1 September 2010 (2010-09-01), pages 568 - 576, XP008177125, ISSN: 1367-6733 *
MERRIFIELD, J AMER CHEM SOC, vol. 85, no. 14, 1963, pages 2149 - 2154
MIKHAYLOV ET AL.: "Ferri-Liposomes as a Novel MRI-Visible Drug Delivery System for Targeting Tumours and their Microenvironment", NAT. NANOTECHNOL., vol. 6, 2011, pages 594 - 602
MUNGER ET AL., BIOCHEM. J., vol. 311, 1995, pages 299 - 305
POCKROS ET AL., HEPATOLOGY, vol. 46, no. 2, 2007
RODRIQUEZ ET AL., J. EXP. MED., vol. 184, 1996, pages 2067 - 2072
SALPETER ET AL.: "A Novel Cysteine cathepsin inhibitor Yields Macrophage Cell Death and Mammary Tumor Regression", ONCOGENE, 2015, pages 1 - 13
SAUNDERS ET AL., ANAL. BIOCHEM., vol. 284, 2000, pages 114 - 124
TURK ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1824, 2012, pages 68 - 88
UENO, H. ET AL., BIOORG. MED. CHEM. LETT., vol. 19, 1997, pages 199
VAN DER LINDEN ET AL.: "Cysteine Cathepsins as Anti-Ebola Agents", ACS INFECT. DIS., vol. 2, no. 3, 2016, pages 173 - 179
VAN DER LINDEN, W. ET AL., ACS INFECTIOUS DISEASES, vol. 2, no. 3, 2016, pages 173 - 179
YAKOVLEV ET AL., J. NEUROSCI., vol. 17, 1997, pages 7415 - 7424
YAN ET AL., BIOL. CHEM., vol. 379, 1998, pages 113 - 123
YAOITA ET AL., CIRCULATION, vol. 97, 1998, pages 276 - 281

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3766873A4 (en) * 2018-03-13 2021-12-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing caspase inhibitor
WO2020181165A1 (en) * 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
US11597703B2 (en) 2019-03-07 2023-03-07 Histogen, Inc. Caspase inhibitors and methods of use thereof
US12071412B2 (en) 2019-03-07 2024-08-27 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
CN110893171A (en) * 2019-12-30 2020-03-20 济源市万洋华康生物科技有限公司 Preparation method of composition for inhibiting wound cicatricial healing
CN110893171B (en) * 2019-12-30 2021-07-27 河南希百康健康产业有限公司 Preparation method of composition for inhibiting wound cicatricial healing
CN114504637A (en) * 2020-09-04 2022-05-17 复旦大学附属中山医院 Application of GSDMD inhibitor in atherosclerosis
CN114504637B (en) * 2020-09-04 2024-05-14 复旦大学附属中山医院 Application of GSDMD inhibitor in atherosclerosis
WO2022261473A1 (en) * 2021-06-11 2022-12-15 The Scripps Research Institute Protease inhibitors for the treatment of coronavirus infections
US11708348B2 (en) 2021-06-11 2023-07-25 The Scripps Research Institute Protease inhibitors for treatment of coronavirus infections

Similar Documents

Publication Publication Date Title
US10167313B2 (en) Selective caspase inhibitors and uses thereof
WO2017053864A1 (en) Cysteine protease inhibitors
US10975119B2 (en) Selective cysteine protease inhibitors and uses thereof
JPH06504547A (en) Peptide ketoamides, keto acids and ketoesters
WO2023275357A1 (en) Caspase-2 inhibitor compounds
US9045524B2 (en) Selective caspase inhibitors and uses thereof
CN118146308A (en) Cyclic peptides for treating gastric cancer and pharmaceutical composition thereof
JP7196113B2 (en) Peptide compound, its application and composition containing it
US20220363718A1 (en) Bicyclic peptide ligands specific for tslp
EP3692051B1 (en) Anticancer peptides and uses thereof
EP4397674A1 (en) Caspase-2 inhibitor compounds
JP3012291B2 (en) Novel peptide, its production method and use
US10385096B2 (en) Pro-Amb reverse turn restricted bioactive peptide analogues
WO2024223883A1 (en) Peptides for cancer therapy
JPH06157588A (en) Cell adhesion active new peptide derivative
JPH07252295A (en) 6,7-dihydroxy-4-thiaheptanoic acid derivative
AU2002359457A2 (en) Methods and compositions for derepression of IAP-inhibited caspase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16778960

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16778960

Country of ref document: EP

Kind code of ref document: A1